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Abstract 
This study was carried out to study the effects of intranasal 
immunization, mucosal adjuvants and vaccine-adjuvant ratio on the 
immunogenicity of Pasteurell multocida in rats. Forty-eight rats were kept in 
a conventional animal house and allowed to adapt to the environment, food 
and water for one week. They were assigned to one of five groups (G1 to 
G5). G1, G2 and G3 were further divided into subgroups (a) and (b) each 
composing 6 rats. Groups 4 and 5 were control groups of 6 rats each. The 
rats were immunized intranasally with P. multocida broth bactrin mixed with 
mucosal adjuvants at day one and day 15. Mucosal adjuvants used were 
olive oil for group 1, sesame oil for group 2 and vitamin D3 for group 3. The 
vaccine adjuvant ratio for all a subgroups was 1:1 and 2:1 for all subgroups 
b. Rats in group 4 received plain P. multocida broth bacterin and rats in 
group 5 were sham-vaccined with phosphate-buffered saline (PBS).  All rats 
were sacrificed on day 21 post initial immunization. Lung and trachea from 
each rat were carefully removed and the trachea and bronchial tree were 
washed thoroughly with 5 ml PBS. The tracheobronchial (TB) lavage was 
collected, centrifuged and the supernatant was kept at -20 ºC for the 
detection of P. multocida specific mucosal Ab using gel diffusion 
precipitation test (GDPT) and indirect haemagglutination (IHA) assay. P. 
multocida whole cell lysate (WCL) was used as antigen for GDPT and for 
coating formalized tanned RBCs. In GDPT, precipitation lines were obtained 
using TB lavage from all Pasteurella multocida intranasally immunized rats, 
and relatively sharp precipitation lines were obtained in  TB lavage of rats of 
G1b, G2a and G3a, indicating the presence of P. multocida specific Ab in 
their TB lavage. The IHA was performed using two-fold dilution of TB 
lavage in v-shaped microtitre plates, starting with 1/200 dilution. Significant 
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(P<0.05) titre were obtained in TB lavage of G1b, G2a and G3a. The IHA 
titre was expressed as the reciprocal of the highest dilution of TB lavage 
showing a diffuse matt of erythrocytes as compared to negative control 
showing a clearly delineated spot of erythrocyte within the vertex of the 
well. Rats of G1b that received P. multocida broth bactrin in olive oil in a 
ratio of 2:1 gave high Ab activity in TB lavage as was determined by IHA 
assay compared to ratio of group 4 ( Adjuvant control) that received plain 
broth bactrin vaccine. This difference is highly significant (P=0.0082). Rats 
in this group G1b showed also higher Ab activity in their TB lavage than 
rats in group 2b that received P. multocida broth bactrin in sesame oil in a 
ratio of 2:1 (P=0.9991) as well as to rats in G3b (P=0.9661). On the other 
hand, rats in group 2a that received P. multocida broth bactrin in sesame oil 
in a 1:1 ratio showed high Ab activity in their TB lavage as determined by 
IHA assay. The Ab titre of this group 2a was significantly higher (P=0.0227) 
than in rats of G2b, G1a and G3b. Similarly, rats in G3a that received P. 
multocida broth bactrin in vitamin D3 in the ratio of 1:1 had significant Ab 
titres in their TB lavage, in comparison to G4 with P values equal to 0.0272. 
In addition, sesame oil and vitamin D3 in 1:1 ratio with P. multocida broth 
bactrin had induced high Ab activity at the respiratory tract, whereas olive 
oil vaccine-adjuvant ratio of 2:1 induced Ab activity of the same magnitude. 
It seems that the booster dose was necessary to ensure a prolonged and 
strong local immune response for P. multocida broth bactrin. Since the 
effectiveness of this broth bactrin vaccine was expected to be much lower 
than live vaccine, mucosal adjuvants as potent delivery systems for antigens 
were incorporated to enhance the uptake of the vaccine-antigen and 
ameliorate the induction of local Ab response at the respiratory tract as 
measured by IHA and GDPT assay.  
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 ﺍﻟﻤﺴﺘﺨﻠﺹ
 ﺍﻟﺘﺤﺼﻴﻥ ﻁﺭﻴﻕﻤﺴﺘﻀﺩﻴﺔ ﺒﻜﺘﺭﻴﺎ ﺍﻟﺒﺎﺴﺘﻴﻭﺭﻴﻼ ﻤﺘﻌﺩﺩﺓ ﺍﻟﻘﺘل ﻋﻥ  ﻟﺩﺭﺍﺴﺔﺃﺠﺭﻱ ﻫﺫﺍﺍﻟﺒﺤﺙ 
ﺍﻟﻤﺴﺎﻋﺩﺍﺕ ﺍﻟﻤﻨﺎﻋﻴﺔ ﺍﻟﻤﺨﺎﻁﻴﺔ ﻭﻤﻌﺩل ﺍﻟﻠﻘﺎﺡ ﻟﻠﻤﺴﺎﻋﺩﺍﺕ ﺍﻟﻤﻨﺎﻋﻴﺔ ﻓﻲ ﺍﻟﺠﺭﺫﺍﻥ ﺍﻟﻤﻤﻨﻌﺔ ﺘﺄﺜﻴﺭ ﻭ ﺒﺎﻷﻨﻑ
ﻴـﺭﺓ  ﻟﻤـﺩﺓ ﺃﺴـﺒﻭﻉ ﺒﺤﻅ ﺍ ﺜﻤﺎﻨﻴﺔ ﻭﺃﺭﺒﻌﻭﻥ ﺠـﺭﺫ  ﺤﻔﻅﺕ .ﻀﺩ ﺒﻜﺘﻴﺭﻴﺎ ﺍﻟﺒﺎﺴﺘﻴﻭﺭﻴﻼ ﻤﺘﻌﺩﺩﺓ ﺍﻟﻘﺘل 
ﻗـﺴﻤﺕ ﺍﻟﺠـﺭﺫﺍﻥ ﺇﻟـﻲ ﺨﻤـﺱ .  ﻭ ﺍﻟﻤـﺎﺀ ﺀ ﺍﻟﻐﺫﺍ ﻟﺘﻘﻠﻴﺩﻴﺔ ﻭﺫﻟﻙ ﻟﻠﺘﻜﻴﻑ ﻋﻠﻰ ﺍﻟﺒﻴﺌﺔ ﻭ ﺍﻟﺤﻴﻭﺍﻨﺎﺕ ﺍ 
 ل ﻜ ﺎﻟﺜﺔ ﻗﺴﻤﺕ ﺇﻟﻲ ﺘﺤﺕ ﻤﺠﻤﻭﻋﺎﺕ ﺃ ﻭ ﺏ،  ﺍﻟﺜﺎﻨﻴﺔ ﻭ ﺍﻟﺜ ﺍﻟﻤﺠﻤﻭﻋﺔ ﺍﻷﻭﻟﻰ ﻭ (.5ﺝ-1ﺝ)ﻤﺠﻤﻭﻋﺎﺕ 
.  ﺠـﺭﺫﺍﻥ 6  ﺒﻬـﺎ  ﻜل ﻤﻨﻬـﺎ  ﺸﺎﻫﺩ ﺍﻟﻤﺠﻤﻭﻋﺔ ﺍﻟﺭﺍﺒﻌﺔ ﻭ ﺍﻟﺨﺎﻤﺴﺔ ﻜﻤﺠﻤﻭﻋﺘﻲ .  ﺠﺭﺫﺍﻥ 6  ﺒﻬﺎ ﻤﻨﻬﺎ
ﺠﺭﺫﺍﻥ ﻋﻥ ﻁﺭﻴﻕ ﺍﻷﻨﻑ ﺒﻠﻘﺎﺡ ﺍﻟﺒﺎﺴﺘﻴﻭﺭﻴﻼ ﻤﺘﻌﺩﺩﺓ ﺍﻟﻘﺘل ﺍﻟـﺫﻱ ﺘـﻡ ﻤﺯﺠـﻪ ﺒﻭﺍﺴـﻁﺔ ﺤﺼﻨﺕ ﺍﻟ 
ﺍﺴـﺘﺨﺩﻤﺕ ﺍﻟﻤـﺴﺎﻋﺩﺍﺕ . ﻋـﺸﺭ ﺍﻟﺨﺎﻤﺱ ﺍﻟﻤﺴﺎﻋﺩﺍﺕ ﺍﻟﻤﻨﺎﻋﻴﺔ ﺍﻟﻤﺨﺎﻁﻴﺔ ﻓﻲ ﺍﻟﻴﻭﻡ ﺍﻷﻭل ﻭ ﺍﻟﻴﻭﻡ 
 ﺯﻴـﺕ ﺍﻟﺴﻤـﺴﻡ ﻟﻠﻤﺠﻤﻭﻋـﺔ ﺍﻟﺜﺎﻨﻴـﺔ ﻭﺯﻴﺕ ﺍﻟﺯﻴﺘﻭﻥ ﻟﻠﻤﺠﻤﻭﻋﺔ ﺍﻷﻭﻟﻰ : ﺔﺘﻴﺍﻟﻤﻨﺎﻋﻴﺔ ﺍﻟﻤﺨﺎﻁﻴﺔ ﺍﻻ 
  ﻜـﺎﻵﺘﻲ  ﻜﺎﻥ  ﺒﺎﻟﻨﺴﺒﺔ ﻟﻠﻤﺴﺎﻋﺩﺍﺕ ﺍﻟﻤﻨﺎﻋﻴﺔ ﺍﻟﻤﺨﺎﻁﻴﺔ ﺡﻤﻌﺩل ﺍﻟﻠﻘﺎ . ﻋﺔ ﺍﻟﺜﺎﻟﺜﺔ   ﻟﻠﻤﺠﻤﻭ 3هﻭﻓﺎﻴﺘﻤﻴﻥ 
ﺤﻘﻨﺕ ﻤﺠﻤﻭﻋﺔ ﺍﻟﺠﺭﺫﺍﻥ ﺍﻟﺭﺍﺒﻌﺔ ﺒﻠﻘﺎﺡ ﺒﻜﺘﻴﺭﻴـﺎ  . ﻟﺘﺤﺕ ﻤﺠﻤﻭﻋﺔ ﺏ 2:1 ﻟﺘﺤﺕ ﻤﺠﻤﻭﻋﺔ ﺃ ﻭ 1:1
.  ﻤﺠﻤﻭﻋﺔ ﺍﻟﺠﺭﺫﺍﻥ ﺍﻟﺨﺎﻤﺴﺔ ﺘﻡ ﺤﻘﻨﻬﺎ ﺒﻤﺤﻠﻭل ﻤﻠﺢ ﺍﻟﻔﻭﺴﻔﺎﺕ ﺍﻟﻤﺘﻌﺎﺩل  ﻭ ﺍﻟﺒﺎﺴﺘﻴﻭﺭﻴﻼ ﻤﺘﻌﺩﺩﺓ ﺍﻟﻘﺘل 
ﺃﺯﻴﻠـﺕ ﺍﻟﺭﺌـﺔ ﻭﺍﻟﻘـﺼﺒﺔ . ﻥ ﻓﻲ ﺍﻟﻴﻭﻡ ﺍﻟﺤﺎﺩﻱ ﻭﺍﻟﻌﺸﺭﻴﻥ ﻤﻥ ﺒﺩﺍﻴﺔ ﺍﻟﺘﺤﺼﻴﻥ ﺸﺭﺤﺕ ﻜل ﺍﻟﺠﺭﺫﺍ 
ﺠﻤﻌـﺕ ﻨـﻭﺍﺘﺞ .  ﻤل ﻤﻥ ﻤﺤﻠﻭل ﻤﻠﺢ ﺍﻟﻔﻭﺴﻔﺎﺕ ﺍﻟﻤﺘﻌـﺎﺩل 5ﺍﻟﻬﻭﺍﺌﻴﺔ ﺒﺤﺭﺹ ﺜﻡ ﻏﺴﻠﺕ ﺒﻭﺍﺴﻁﺔ 
ﺍﻟﻐﺴﻭل ﺍﻟﺭﻏﺎﻤﻲ ﺍﻟﺸﻌﺒﻲ ﻭﺍﺨﺫ ﻁﺎﻓﻲ ﺍﻟﻐﺴﻭل ﺒﻌﺩ ﺍﻟﻁﺭﺩ ﺍﻟﻤﺭﻜﺯﻱ ﻭ ﺤﻔﻅ ﻓـﻲ ﺩﺭﺠـﺔ ﺤـﺭﺍﺭﺓ 
ﻟﻤﻀﺎﺩﺓ ﺍﻟﻤﺨﺎﻁﻴﺔ ﺍﻟﻨﻭﻋﻴﺔ  ﻟﺒﻜﺘﻴﺭﻴﺎ ﺍﻟﺒﺎﺴﺘﻴﻭﺭﻴﻼ ﻤﺘﻌﺩﺩﺓ ﺍﻟﻘﺘل ﺠﺴﺎﻡ ﺍ ﻭﺫﻟﻙ ﻟﻠﻜﺸﻑ ﻋﻥ ﺍﻷ ﻡ º 02 -
  ﻭﺍﺨﺘﺒـﺎﺭ ﺍﻟـﺘﻼﺯﻥ ﺍﻟـﺩﻤﻭﻱ ﺍﻟﻐﻴـﺭ )TPDG( ﺨﺘﺒﺎﺭ ﺍﻻﻨﺘﺸﺎﺭ ﺍﻟﺘﺭﺴﻴﺒﻲ ﺍﻟﻬﻼﻤـﻲ ﺍﺒﺎﺴﺘﺨﺩﺍﻡ 
iv 
ﺍﺴﺘﺨﺩﻤﺕ ﺨﻼﻴﺎ ﺒﻜﺘﻴﺭﻴﺎ ﺍﻟﺒﺎﺴﺘﻴﻭﺭﻴﻼ ﻤﺘﻌﺩﺩﺓ ﺍﻟﻘﺘل ﺍﻟﻤﺤﻠﻠـﺔ ﻜﻤﺴﺘـﻀﺩ ﻻﺨﺘﺒـﺎﺭ  . )AHI(ﻤﺒﺎﺸﺭ
 .ﻤﻌﺎﻟﺠﺔ ﺒﺤﻤﺽ ﺍﻟﺘﺎﻨﻙ ﻭﺍﻟﻔﻭﺭﻤـﺎﻟﻴﻥ ﻴﻑ ﻜﺭﺍﺕ ﺍﻟﺩﻡ ﺍﻟﺤﻤﺭﺍﺀ ﺍﻟ ﺍﻻﻨﺘﺸﺎﺭ ﺍﻟﺘﺭﺴﻴﺒﻲ ﻓﻲ ﺍﻟﻬﻼﻤﺔ ﻭﻟﺘﻐﻠ 
ﺃﻅﻬﺭ ﺍﺨﺘﺒﺎﺭ ﺍﻻﻨﺘﺸﺎﺭ ﺍﻟﻬﻼﻤﻲ ﺨﻁﻭﻁ ﺘﺭﺴﻴﺏ ﻭﺫﻟﻙ ﻋﻨﺩ ﺍﺴﺘﺨﺩﺍﻡ ﻨﻭﺍﺘﺞ ﺍﻟﻐﺴﻭل ﺍﻟﺭﻏﺎﻤﻲ ﺍﻟﺸﻌﺒﻲ 
ﻭ ﺤﺼل ﻋﻠﻰ ﺨﻁـﻭﻁ . ﻓﻲ ﻜل ﺍﻟﺠﺭﺫﺍﻥ ﺍﻟﻤﻤﻨﻌﺔ ﺒﺒﻜﺘﻴﺭﻴﺎ ﺍﻟﺒﺎﺴﺘﻴﻭﺭﻴﻼ ﻤﺘﻌﺩﺩﺓ ﺍﻟﻘﺘل ﺒﻭﺍﺴﻁﺔ ﺍﻷﻨﻑ 
ﺏ ﻭ 1ﺭﻏﺎﻤﻲ ﺍﻟﺸﻌﺒﻲ ﻟﺠﺭﺫﺍﻥ ﺘﺤﺕ ﻤﺠﻤﻭﻋﺔ ﺝ ﺘﺞ ﺍﻟﻐﺴﻭل ﺍﻟ ﺘﺭﺴﻴﺏ ﺒﺼﻭﺭﺓ ﻭﺍﻀﺤﺔ ﻨﺴﺒﻴﺎ ﻤﻥ ﻨﻭﺍ 
ﻭﺫﻟﻙ ﻟﻭﺠﻭﺩ ﺍﻟﺠﺴﻡ ﺍﻟﻤﻀﺎﺩ ﺍﻟﻨﻭﻋﻲ ﻟﺒﻜﺘﻴﺭﻴﺎ ﺍﻟﺒﺎﺴﺘﻴﻭﺭﻴﻼ ﻤﺘﻌﺩﺩﺓ ﺍﻟﻘﺘـل ﻓـﻲ ﻨـﻭﺍﺘﺞ ﺃ 3ﺃ ﻭ ﺝ 2ﺝ
ﺍﺠﺭﻱ ﺍﺨﺘﺒﺎﺭ ﺘﻼﺯﻥ ﺍﻟﺩﻡ ﺍﻟﻐﻴﺭ ﻤﺒﺎﺸﺭ ﺒﺎﺴﺘﺨﺩﺍﻡ ﺍﻟﺘﺨﻔﻴﻑ ﺍﻟﻤـﻀﺎﻋﻑ ﻟﻨـﻭﺍﺘﺞ ﺍﻟﻐـﺴﻭل . ﺍﻟﻐﺴﻭل
ﺘﻡ ﺍﻟﺤﺼﻭل .  002/1ﺍﺒﺘﺩﺍﺀ  ﺒﺎﻟﺘﺨﻔﻴﻑ  v  ﺍﺕ ﺍﻟﺸﻜلﺍﻟﺩﻤﻭﻱ ﺫ ﻥﺍﻟﺭﻏﺎﻤﻲ ﺍﻟﺸﻌﺒﻲ ﻓﻲ ﺃﻁﺒﺎﻕ ﺍﻟﺘﻼﺯ
ﺃ 2 ﺝ ﺏ ﻭ 1ﺭﻏﺎﻤﻲ ﺍﻟﺸﻌﺒﻲ ﻓﻲ ﺘﺤﺕ ﻤﺠﻤﻭﻋـﺎﺕ ﺝ ﻋﻠﻰ ﻤﻌﻴﺎﺭ ﻋﺎﻟﻲ ﺍﻟﻤﻌﻨﻭﻴﺔ ﻓﻲ ﻨﻭﺍﺘﺞ ﺍﻟﻐﺴﻭل ﺍﻟ 
ﻭﻴﻌﺘﺒﺭ ﻤﻌﻴﺎﺭ ﺍﺨﺘﺒﺎﺭ ﺍﻟﺘﻼﺯﻥ ﺍﻟﺩﻤﻭﻱ ﺍﻟﻐﻴﺭ ﻤﺒﺎﺸﺭ ﻤﻘﻠﻭﺏ ﻷﻋﻠﻰ ﺘﺨﻔﻴﻑ ﻤﻥ ﻨﻭﺍﺘﺞ ﺍﻟﻐﺴﻭل . ﺃ3ﻭﺝ
 ﺸﺎﻫﺩﻜﺭﺍﺕ ﺍﻟﺩﻡ ﺍﻟﺤﻤﺭﺍﺀ ﻤﻘﺎﺭﻨﺔ ﺒﻤﺠﻤﻭﻋـﺔ ﺍﻟ  ـﺍﻟﺭﻏﺎﻤﻲ ﺍﻟﺸﻌﺒﻲ  ﺍﻟﺘﻲ ﺘﻅﻬﺭ ﻜﻭﺴﺎﺩﺓ ﻤﻨﺘﺸﺭﺓ ﻤﻥ 
ﻠﻘﺎﺡ ﺍﻟﺒﺎﺴﺘﻴﻭﺭﻴﻼ ﻤﺘﻌـﺩﺩﺓ ﺤﻘﻨﺕ ﺒ ﺍﻟﺠﺭﺫﺍﻥ ﺍﻟﺘﻲ . ﺍﻟﺴﺎﻟﺒﺔ ﺍﻟﺘﻲ ﺘﻅﻬﺭ ﻜﺒﻘﻌﺔ ﻤﺘﺠﻤﻌﺔ ﻓﻲ ﻗﺎﻉ ﺍﻟﻁﺒﻕ 
 ﺃﻋﻠﻰ ﻓﻌﺎﻟﻴﺔ ﻟﻸﺠﺴﺎﻡ ﺍﻟﻤـﻀﺎﺩﺓ ﻓـﻲ ﻨـﻭﺍﺘﺞ ﺍﻟﻐـﺴﻭل ﺕ ﺃﻋﻁ 2:1ﺍﻟﻘﺘل ﻤﻊ ﺯﻴﺕ ﺍﻟﺯﻴﺘﻭﻥ ﺒﻤﻌﺩل 
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 1
INTRODUCTION 
 
Haemorrhagic septicaemia (HS) remains a disease of major economic 
importance in the Sudan. In the Sudan, the disease is caused by P.multocida 
types B6 and E6 (Shigidi and Mustafa, 1979). Although the disease has been 
described since the turn of the last century, little is known about its 
pathogenesis. Virulence markers identified in other bacteria have not been 
well documented in P.multocida, apart from the fact that the capsule is 
essential for pathogenicity (De Alwis, 1990). 
Although the disease was described originally as septicaemia, it is 
believed that the septicaemia in most instances is a terminal event and most 
likely it is preceded by a descending colonization of the respiratory tract by  
P.multocida causing an acute inflammatory response that might damage the 
alveolar septa permitting the bacteria to reach the blood circulation in high 
numbers fulminating in septicaemia. The instrumental inflammatory cells 
are activated alveolar macrophages. Death that follows is probably due to 
septic shock as in the case of other Gram negative bacteria. This has led to 
the hypothesis of pulmonary compartmentalization where a barrier is 
postulated that must be overcome before infection is systemically 
disseminated. Therefore, due to the sudden onset, brief duration and fatal 
nature of the disease, treatment in most cases is not possible and the only 
satisfactory and practical method of control and prevention is by carrying 
out timely vaccination of all healthy and in contact animals and adopting 
hygienic measures. Bacterins made from P.multocida have been available 
for many decades but with little effect in preventing the disease. Other major 
problems associated with these vaccines include: Generate systemic immune 
response rather than effective local immunity, occasional outbreaks in areas 
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covered by vaccination, produced post-vaccination shock, induce immune-
enhancement following exposure to natural or experimental infection (De 
Alwis, 1990). Nonetheless, investigations into the immunologic potential of 
P.multocida over the last several years have led to the development of a 
variety of immunoprophylactic agents, but none of them has yet replaced the 
old bacterin vaccine (De Alwis, 1990). For most mucosal diseases of the 
respiratory tract, the induction of local immunity at the site of infection is 
crucial for optimal protection (Cox, Verdonck, Vanrompay and Goddeeris, 
2006). In the immune animal, it is believed that the locally generated Abs of 
SIgA might abort early sequences of this disease to occur and hence SIgA 
confer protection against this disease without local or systemic involvement 
(Gerdts, Mutwiri, Tikoo and Babluk, 2006). 
Since the effectiveness of HS bactrins vaccines is expected to be 
much lower than live vaccine, a potent adjuvant and delivery systems are 
needed to enhance the uptake of vaccine antigen and to increase the 
induction of immunity (Gerdts et al., 2006). As a result, in this study 
intranasal route might be more favorable for inducing immunity at the 
respiratory tract, which constitutes the desired effector site for protection 
against haemorrhagic septicaemia.  
The primary reasons for using intranasal route of immunization is that 
P. multocida infection affect or initiate the infectious process at the upper 
respiratory mucosal surface, hence mucosal application of the vaccine, 
preferably in mucosal adjuvant, is required to induce a protective immune 
response (Holmgren and Czerkinsky, 2005). Therefore, induction of local 
immunity at site of infection is crucial for optimal protection. The induction 
of SIgA represents the main effector mechanism of the local adaptive 
immune response, thus represents the primary goal for most mucosal 
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vaccines. Moreover, mucosal immunization induces both mucosal and 
systemic immunity with mucosal memory. If immunity wanes upon second 
exposure to P. multocida, there will be a rapid response both locally and 
systemically, (Cox et al., 2006). The principle objectives of this study were 
1. To evaluate immunogenicity of P. multocida in rats. 
2. To induce a local immune response at the respiratory tract using 
intranasal route. 
3. To evaluate the effect of mucosal adjuvants in enhancing a local 
immune response. 
4. To evaluate mucosal immunization in the generation of a local 
immune response.  
  
        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER ONE 
LITERATURE REVIEW 
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2.1. Haemorrhagic Septicaemia 
Haemorrhagic Septicaemia (HS) is a peracute, contagious and highly 
fatal septicaemic disease of both wild and domestic animals, with endemic 
nature in most parts of tropical and subtropical Asia and Africa (Bain, 1957). 
2.1.1. Etiology 
 Hemorrhagic septicemia is caused by two serotypes of P. multocida; 
B 2 and E 2. The letter denotes the capsular antigen as determined originally 
by the indirect hemagglutination test of Carter (Carter, 1984), and the 
numeral 2 stands for the somatic or O antigen as determined by the agar gel 
diffusion precipitin test developed by Heddelston and associates (Namioka 
and Bruner, 1963). This somatic antigen 2 is the equivalent to the 6 in the 
classification of Namioka and associates. In a new classification, Pasteurella 
multocida strains causing most pasteurella infections, including hemorrhagic 
septicemia, are called P. multocida subspecies multocida. 
2.1.2. Taxonomy of   Pasteurella multocida 
Pasteurella multocida (P.multocida) belong to the family 
Pasteurellaceae which contains the genera Pasteurella, Actinobacilluss, 
Gallibacteria, Haemophilus, Lonepinella, Mannheimia and 
Phocoenobacter.These genera share a number of common features and some 
organisms have been reclassified within these genera following 
deoxyribonucleic acid hybridization studies and 16 rRNA sequencing 
(Quinn, Markey, Carter, Donnelly and Leonard, 2002). 
 
 
2.1.3. Cultural, Morphological and Biochemical Characterization 
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Pasteurella multocida species can be identified on the bases of 
cultural, morphological and biochemical characteristics. Topley and Wilson 
(1929) described P. multocida, as small, ovoid, Gram negative bacilli with 
bipolar staining characteristics, which are aerobic, facultatively anaerobic 
and produce indole and ferment carbohydrates with slight gas production. 
2.1.4. Biotypes of Pasteurella multocida 
        Five biovars of P.multocida were proposed by (Carter, 1967) 
designated as biovar a (the mucoid biovar), biovar b (the haemorrhagic 
septicaemia biovar), biovar c (the porcine biovar), biovar d (the feline 
biovar) based upon hyaluronidase decapsulation, acriflavine folliculation, 
colonial iridescence, fermentation pattern, mouse pathogenicity, host 
predilection and serologic and immunologic characteristic. The fifth biovar 
is designated e (deer biovar) on the bases of its acid reactions in trehalose, 
sorbitol, mannitol and their failure to produce hydrogen sulphide 
(Frederiksen, 1973). 
2.1.5. Antigenic structure and serotypes of Pasteurella multocida 
  Different methods, employing a wide range of antigenic components 
and cellular fractions were adopted to serotype P.multocida Roberts, (1947) 
classified strains of P. multocida into 4 serological types I, 11, 111 and IV 
by the passive mouse protection tests in which mice were passively 
immunized by antisera prepared against one strain and counter challenged 
by the homologous or heterologous virulent cultures of the strain. The 
colonial morphology and antigenic behavior of variants of P.multocida 
employing the S, R and M designation of Carter, (1957), using the 
acriflavine test revealed a characteristic reaction when freshly isolated type 
D P. multocida were subjected to the test. The test rapidly identified the non-
immunogenic cultures of P. multocida together with the untypable ones. In 
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1955, Carter described a haemagglutination test for identifying P. multocida 
utilizing specific capsular antigens and capsular hyaluronic acid extracted by 
heating the cells at 56°C for 30 minutes in normal saline. These were 
adsorbed to human group (O) erythrocytes and positive results were detected 
by visible agglutination. The test recognized four different serological 
groups designated A, B, C and D and failed to allocate non encapsulated 
cultures to any specific group. When compared to Roberts type I, 11, III & 
IV they were found to be identical to type B, A, C and D, respectively. 
Carter, (1967) identified a strain  of P. multocida isolated from cattle with an 
acute septicaemic disease which was different from that caused by serotype 
B P. multocida in cattle and buffaloes and designated it as serotype E . His 
serotype C gave inconclusive results in further studies and was dropped as a 
distinct serological group. (Rimer and Rhoades, 1986) identified an 
additional capsular serogroup designated serogroup F among P.multocida 
isolated from turkeys in USA with somatic serogroups I, 3, 7 and 12. 
Namioka and Murata (1961) studied the antigenic relationships between the 
somatic antigens (O-Ag) of P.multocida prepared by treating cultures of the 
organism with normal hydrochloric acid (N-HCL) and divided them into 
common and specific antigens. Cultures of type A and D were divided into 
two groups according to their O-Ag. Sub culturing of the organisms did not 
change the O-Ag into the rough form even if it was repeated for a year or 
more. They distinguished 6 somatic groups (1-6) among 24 strains of P. 
multocida from different parts of the world by means of absorption tests and 
consequently 6 serotypes were specified by combining their capsular types 
and somatic groups. 
 
2.1.6. Epidemiology 
 7
  The scope of epidemiology in modern animal husbandry practice is 
continuously widening. Epidemiological data provide information on 
various diseases which are pre-requisite for planning, execution and 
monitoring of disease control programmes. It is an important requirement for 
assessing economic impact of a disease and for developing disease 
forecasting system. 
2.1.7. Hosts 
De Alwis (1990) reported that the major animal species susceptible to 
HS were buffaloes and cattle. Buffaloes were found more susceptible than 
cattle and that in both species, young and adult animals were found more 
susceptible than older animals. Analysis of 26 recorded outbreaks of HS in 
buffaloes and cattle in various districts of Haryana (India) from 1995 to 
1999 revealed higher disease prevalence in buffaloes than in cattle (Jindal, 
Kumar, Narang, Chaturvedi, Tomar and Garg, 2002).   
2.1.8. Geographical Distribution of HS 
An outbreak of HS is believed to begin when a ‘latent carrier’ animal 
becomes active and sheds virulent organisms infecting in-contact susceptible 
animals. Once a clinical case is established, dissemination of infection will 
increase and the magnitude of the outbreak that results will depend on the 
proportion of immune to non-immune animals in the herd (De Alwis, 1990). 
Hemorrhagic septicemia has a worldwide distribution and is endemic in 
Africa and Asia. In Africa, it was reported in most countries (Annosa and 
Isoun, 1975). The disease was found across Asia from the Middle East 
region to south eastern Asia (Anonymous, 1979).  
 
 
2.1.9. Haemorrhagic Septicaemia in Sudan 
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  The disease is endemic in Sudan and was reported nearly from all 
parts of the country. The disease was reported in Blue Nile province (1933), 
kassala (1939), Northern Kordofan (1943), and Upper Nile (1947). (Sud.     
Vet. Serv. 1933, 1939, 1943 and 1947). Serotypes B 6 and E 6 were isolated 
and identified from natural cases of Hemorrhagic septicemia in cattle by 
Shigidi and Mustafa in (1979). The disease was also reported as an acute 
pasteurellosis in camels in the Blue Nile province by (Hassan and Mustafa, 
1985) and serotype B 6 was identified as the causative agent of the disease.  
2.2. Pathogenicity and immunogenicity 
 Pasteurella multocida, a Gram-negative facultative bacterium, is one 
of the notorious animal pathogens causing widespread infections in various 
domestic animals; snuffles in rabbits, pneumonia and haemorrhagic 
septicaemia in cattles, sheep and goats and fowl cholera in chickens. In pigs, 
it causes severe respiratory diseases such as atrophic rhinitis (AR) and 
pneumonic pasteurellosis (Vasfi, Marandi and Mittal, 1997). Significant 
global economic loss in swine production due to growth retardation is 
caused by AR, and therefore, vaccination has merged as the most attractive 
and effective approach in controlling AR (Liao, Huangb, Hsuan, Chenb, 
Lee, Liu, Winton and Chien, 2006). Currently used vaccines, including 
inactivated and live vaccines, have their intrinsic problems as well as several 
advantages (Lubke, Hartmann, Schroder and Hellmann, 1994). A major 
advantage of live attenuated vaccines is that they are able to stimulate cross 
protection against different P. multocida serotypes. However, because the 
basis for attenuation is not known, it is not surprising that vaccinated flocks 
with live attenuated vaccines suffer outbreaks. Moreover, when a killed 
bacterium was used for vaccination, immunity is generally serotype-specific 
(Carpenter, Snipes, Kasten, Hird and Hirsh, 1991). The outer membrane of 
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Gram-negative bacteria contains lipopolysaccharides, several minor proteins 
and a limited number of major proteins present in very high copy numbers. 
One of the major outer membrane proteins, bacterial porins, functions as 
channels for the entrance and exit of hydrophilic low-molecular-weight 
substances. Porins have high immunogenicity as well as antigenicity, 
exposing epitopes on the bacterial surface. They are generally conserved in a 
bacterial species or even in bacterial families, and also share strong 
taxonomic associations in that they have high homology in both primary 
amino acid sequence and secondary structure (Jeanteur, Lakey and Pattus, 
1991). Because of these properties, porins can be attractive vaccine 
candidates for heterologous immunity against Gram-negative bacterial 
infections (Rimler, 1996). Porin H is the major outer membrane protein in 
the envelope of P. multocida and conserved in several serotypes of P. 
multocida (Chevalier, Duclohier, Thomas, Shechter and Wroblewski, 1993). 
This protein exists as homotrimer in outer membrane, and the molecular 
weight of denatured monomer varies from 34 to 42 kDa (Chevalier et al., 
1993). The differences of the outer membrane protein H gene (ompH) by 
serogroups or serotypes in P. multocida are thought by the variety of the 
length and the sequence of the two variable regions in the oomph gene 
functioning as specific epitopes. The OmpH is a homologue of the P2 porin 
of Haemophilus infuenzae and a monoclonal antibody against OmpH could 
passively protect mice against infection (Vasfi et al., 1997). 
2.3. Diagnosis of HS 
Clinical diagnosis of HS is based on a combination of clinical signs, 
gross pathological lesions, epidemiology and history of previous occurrence 
of HS in herd. Diagnostic tests for HS include culture and biological tests for 
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isolation of the organism, biochemical and serological tests (stereotyping) 
and molecular methods for strain differentiation within the serotype. 
2.3.1. Isolation 
Blood or blood swab from the heart or from jugular vein or from 
freshly dead case should be stored on ice until it reaches the laboratory. 
Blood collected from clinical cases prior to death is not reliable since 
septicaemia is a terminal event (Shigidi and Mustafa, 1979). A small volume 
(0.2 ml) of suspension is inoculated into mouse by S/C or I/M route. If HS 
organisms are present, the mice will die within 24 hours. 
2.3.2. Microscopy  
     Characteristic bipolar staining of short bacilli of pasterella multocida 
organisms in blood or tissue smears stained with methylen blue or gram 
positive stain indicative infection with P.multocida. 
2.3.3. Cultural Characteristic  
Pure cultures of P.multocida can be obtained from collected samples 
streaked onto blood agar. Large, smooth, non mucoid grayish colonies 1-2 
mm in diameter can be obtained if enriched media such as tryptose agar with 
yeast extract or casein-sucrose-yeast agar are used (Wijewardana, DeAlwis 
and Bashansz, 1986). 
2.3.4. Serological tests (serotyping) 
Confirmatory diagnosis is made by serotyping the cultured organism 
using rapid slide agglutination (Namioka and Murata, 1961) and indirect 
heamagglutination assay by Carter for capsular typing B2 or E2 biotypes 
(Carter 1955, 1961). Other tests include, agglutination test for somatic 
typing, agar gel immunodiffusion or counter immunoelectrophoresis assays 
for rapid identification of type B and E (Carter and Chengappa, 1980), tube 
agglutination test and the serum bactericidal test (Bain, 1963). Recently an 
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enzyme linked immuno-sorbent assay ELISA for identification of 
P.multocida was developed by Dawkins, Johnson, Spencer and Paten, 
(1990).  
Somatic typing by agglutination test using HCL treated cells was 
employed by Namioka and Murata (1961) to determine type 6 somatic 
antigen which causes HS. Agar gel immunodiffusion using heat stable 
supernatant antigen to determine 2 and 5 somatic antigen was used by 
Heddleston, Gallagher and Rebers, (1972). 
2.3.5. Molecular methods of diagnosis  
  Phenotypic identification of P.multocida based on biochemical 
reactions is often limited and usually only done on a species level, even 
though three subspecies are described. For molecular taxonomy and 
diagnostic purposes, a phylogenetic analysis of the three subspecies of 
P.multocida based on their 16S Rrna (rrs) gene sequence belongs to 
P.multocida subsp. Septica a distinguished branch on the phylogenetic tree 
of pasteurellaceae, due to a 1.5% divergence of its rrs gene compared to the 
other two, more closely related subspecies multocida and gallicida. This 
phylogenetic divergence can be used for the identification of P.multocida 
subsp. Suptica by rrs gene determination since they form a phylogenetically 
well isolated and defined group as shown with a set of feline isolates. The 
sequence based identification shows the advantages over conventional 
methods. It is therefore helpful for future unambiguous identification and 
molecular taxonomy of P.multocida as well as for epidemiological 
investigations (Kuhnert, Boerlin, Emler, Krawinkler and Frey, 2001). 
Molecular detection by PCR offers a more sensitive, specific, time-saving 
method for detecting pasteurella and confirming infection (Miflin and 
Blackall, 2001).  
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2.4. Immunity   
       The immune system protects organisms from infection with layered 
defenses of increasing specificity. Physical barriers prevent pathogens such 
as bacteria, fungi and viruses from entering the body. If a pathogen breaches 
these barriers, the innate immune system provides an immediate, but non-
specific response. Innate immune systems are found in man and animals 
(Litman, Cannon and Dishaw, 2005).  However, if pathogens successfully 
evade the innate response, vertebrates possess a third layer of protection, the 
adaptive immune system, which is activated by the innate response. Here, 
the immune system adapts its response during an infection to improve its 
recognition of the pathogen. 
2.4.1. Innate immunity 
Microorganisms that successfully enter a host will encounter the cells 
and mechanisms of the innate immune system of that host. The innate 
response is usually triggered when microbes are identified by pattern 
recognition receptors, which recognize components that are conserved 
among broad groups of microorganisms (Medzhitov, 2007). Innate immune 
defenses are non-specific, meaning these systems respond to pathogens in a 
generic way (Alberts, Johnson, Lewis, Raff, Roberts, and Walters, 2002). 
This system does not confer long-lasting immunity against a pathogen. The 
innate immune system is the dominant system of host defense in most 
organisms (Litman et al., 2005). 
2.4.2. Adaptive immunity 
The adaptive immune system evolved in early vertebrates and allows 
for a stronger immune response as well as immunological memory, where 
each pathogen is "remembered" by a signature antigen (Pancer and Cooper, 
2006). The adaptive immune response is antigen-specific and requires the 
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recognition of specific “non-self” antigens during a process called antigen 
presentation. Antigen specificity allows for the generation of responses that 
are tailored to specific pathogens or pathogen-infected cells. The ability to 
mount these tailored responses is maintained in the body by "memory cells". 
Should a pathogen infect the body more than once, these specific memory 
cells are used to quickly eliminate it. B cells and T cells are the major types 
of lymphocytes and are derived from hematopoietic stem cells in the bone 
marrow. (Janeway, 2005). B cells are involved in the humoral immune 
response, whereas T cells are involved in cell-mediated immune response. 
2.5. Immunity to P.multocida 
  The type of immunity developed against P.multocida is mainly 
antibody mediated. Lipopolysaccharide (LPS) of P.multocida stimulates 
humoral immunity, and it considered to be a protective antigen 
(Wijewardana and Sutherland, 1990). Nagy and Penn (1976) reported that 
antibody level in vaccinated cattle determined by passive mouse protection 
(PMP) test indicated that immunity to HS is exclusively antibody mediated. 
The duration and the magnitude of these responses are affected by many 
factors such as virulence, potency of the antigen, the dosage, and the method 
of induction and the age of the animal. P.multocida strains are classified into 
Heddleston serotypes based on the antibody responses to LPS, while 
antibodies raised against heat-killed P.multocida vaccines are directed 
primarily against LPS and protect the host against strains within the same 
serotype (Brogden and Rebers, 1978). LPS purified using the Westphal 
method and injected into mice and rabbits resulted in poor antibody response 
and no protection against  P.multocida infection. In contrast, LPS injected 
into chickens induced a good antibody response which passively protected 
recipients against disease (Rebers, Phillips, Rimler, Boykins and Rhoades, 
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1980) In addition, an opsonic monoclonal antibody against LPS from a 
serotype B strain of  P.multocida was shown to partialy protect mice against  
P.multocida infection (Ramdani and Adler, 1991) whereas monoclonal 
antibodies raised against the LPS from a serotype A strain were shown to be 
bactericidal and completely protect mice against homologous challenge 
(Wijewardana, Wilson, Gilmour and Poxton, 1990). LPS was found to 
stimulate TNF-α release from bovine alveolar macrophages and many other 
tumour inhibition factors and interleukins were released and triggered by the 
mitogenic action of the endotoxins. The mitogenic action was explained 
through the disturbance in the host cellular mechanisms, leading to cellular 
proliferation and blocking apoptosis (Horadagoda, Hodgson, Moon, 
Wijewardana and Eckersall, 2002). 
2.5.1. Types of immunity to HS 
Types of immunity to HS are recognized as naturally aquired, artifitial 
active or passively inducible. 
2.5.1.1. Active natural immunity 
In endemic areas, regular outbreaks of HS occur mostly during the 
wet season, depending on an interaction between a numbers of factors 
(burden of infection, host defense mechanism, immunity level). Some 
animals succumb to clinical disease while others will develop what is 
described as an arrested infection leading to a naturally acquired immunity 
(De Alwis, 1987). Thus, in endemic areas, the adult population through 
successive exposures acquires natural immunity and only small numbers of 
hitherto unexposed animals will remain susceptible at each outbreak. It is 
assumed that morbidity and mortality due to HS in a given population 
largely depend on the proportion of an immune to non-immune animals and 
the phenomenon of naturally acquired immunity is responsible for the 
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different patterns of morbidity and mortality in endemic and non endemic 
areas. 
2.5.1.2. Active artificial immunity (Vaccination)     
Vaccination is generally accepted as the best mean of control against 
pasteurellosis and vaccines in different forms are readily available 
throughout the world. 
2.5.1.3. Passive artificial immunity 
Mosier, Confer and Panciera (1989) reviewed the evolution of 
vaccines for bovine pneumonic pasteurellosis, where they stated that the use 
of HS antisera to induce passive immunity to HS was practiced since 1918. 
The use of HS antisera was found to be of value when given before shipment 
to control shipping fever. 
   2.6. Mucosal immunity 
       The mucosal surfaces of the gastrointestinal and respiratory tracts 
represent the principal portals of entry for most pathogens. The mucosal 
surfaces represent a critical component of the mammalian immunologic 
repertoire. The major antibody isotype in external secretions is secretory 
immunoglobulin A (S-IgA). Approximately 40 mg of IgA per kg of body 
weight is secreted daily, especially from the gastrointestinal tract, and the 
total amount of IgA synthesized is almost twice the amount of IgG produced 
daily in humans (Conley and Delacroix, 1987). It is, however, interesting 
that the major effecter cells in the mucosal surfaces are not IgA B cells, but 
T lymphocytes of CD4+ as well as CD8+ phenotypes. It is estimated that T 
lymphocytes may represent up to 80% of the entire mucosal lymphoid cell 
population.  
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2.7. Common mucosal immunology 
Mucosal inductive sites such as the Peyers patches in the intestinal 
tract and the nasal-associated lymphoreticular tissue in the oropharyngeal 
cavity, stand as sentinels to the intestinal and respiratory tracts and represent 
the major sites where mucosal immune responses are initiated (Figure: 1:1). 
Common features of these inductive sites are microfold although the precise 
function of M cells has not yet been established; recent studies indicate that 
they are involved in the uptake, transport, processing, and possibly 
presentation of microbial antigens (Neutra, Frey and Kraehenbuhl, 1996). 
The interaction of epithelial cells with T and B lymphocytes induces 
epithelial cells to differentiate into M cells in vitro, indicating the 
importance of lymphocyte-epithelial cell interactions for maintaining M 
cells in the follicle-associated epithelium of the Peyer’s patches (Jones, 
Ghori and Falkow, 1994). These lymphocyte-M cell interactions can occur 
in the pocket of the M cells and are mediated through thin cellular 
extensions, indicating that cell-cell interactions are an intricate part of the 
M-cell function and that they may facilitate transfer of luminal antigens. 
2.7.1. T-Cell and Cytokine Involvement in B-Cell Isotype Commitment 
to IgA 
Although the variables involved in the switching of B cells to 
polymeric IgA (pIgA) producing plasma cells have been studied, many 
questions remain. In recent years, gene-deleted or knockout mice have 
contributed to a better understanding of the role of specific cells, cytokines, 
and surface molecules involved in IgA isotype switching. Presumably, 
isotype switching occurs in mucosal inductive sites, while IgA production by 
plasma cells occurs in mucosal effector sites, separating the IgA switching 
and IgA secretion by B cells into different immune compartments (McGhee, 
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Lamm and Strober, 1999). Each of these stages requires specific signals, 
such as co stimulatory molecules, cytokines, and T-helper cells, to give rise 
to antigen specific S-IgA Abs in mucosal effector sites. Neither Th1- nor 
Th2-type cytokines contribute significantly to the switching of B cells to 
surface IgA positive (sIgA+) B cells (Figure: 1: 2). This process requires the 
presence of transforming growth factor ßð1 (TGF-ßð1), which can activate 
the switching of B cells to the IgA isotype (Ehrhardt, Strober and Harriman, 
1992). TGF-ßð1 induces a small proportion (<2%) of B cells to switch to 
IgA in activated B-cell cultures (Ehrhardt et al., 1992). However, TGF- ßð1, 
when used in combination with additional signals, increased TGF-ßð1-
induced switching in 10% to 20% of B cells and approached IgA+ B-cell 
levels observed in Peyer’s patches (McIntyre, Kehry and Snapper, 1995). 
Thus, multiple activation signals contribute to the switch to IgA, i.e., B-cell 
activation by cross-linking the B-cell antigen receptor, CD40-CD40L 
interactions to promote switching, TGF-ßð1 by directing the switch to IgA, 
and Th2-type cytokines by increasing the number of post-switch IgA+ B 
cells and their differentiation into IgA-secreting plasma cells. In addition, 
activated T cells and dendritic cells from the Peyer’s patches are more 
effective in switching sIgM+ sIgA- B cells to IgA-producing cells than were 
T cells and dendritic cells derived from the spleen (Spalding, Williamson, 
Koopman and McGhee, 1984). This suggests that mucosal inductive sites 
contain specialized T cells or dendritic cells beneficial for B cells to 
differentiate into IgA-producing cells. Thus, either Th1 or Th2 cells or a 
combination of these cell types can support antigen-specific S-IgA Ab 
responses. In this respect, Th2-type cytokines play a role in terminal 
differentiation of B cells, that are already committed to IgA (Briere, Bridon, 
Chevet, Souillet, Bienvenu and Guvet, 1994), while the Th1- type cytokine 
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IFN-γð has been implicated in the induction of the polymeric Ig receptor 
(pIgR needed for transport of S-IgA (Wira, Richardson and Prabhala, 1994). 
Cross inhibition of Th1 and Th2 cell-directed IgG2a and IgE production was 
mediated through IFN-γð and IL-4, respectively (Figure 1:2) (Rizzo, 
DeKruyff, Umetsu and Caspi, 1995). 
2.7.2. Mucosal S-IgA Antibody Responses 
The hallmark of the mucosal immune system is the production of S-
IgA. S-IgA results from transcytosis of dimeric IgA across the epithelium 
through binding to the pIgR. S-IgA is released from the pIgR by cleavage of 
the receptor, resulting in pIgA covalently associated with a substantial part 
of the pIgR, i.e., the secretory component (Mostov, 1994). This complex, 
referred to as S-IgA, seems to be more resistant to proteolysis in external 
secretions. Furthermore, transport of pIgA containing immune complexes 
across epithelial cells expressing the pIgR is another defense mechanism of 
the mucosal immune system against pathogen entry (Kaetzel, Robinson and 
Lamm, 1994). These characteristics of pIgA are beneficial in preventing 
infection and inflammation at epithelial surfaces. 
2.8. Common Mucosal Immune System 
The immunologic network operating on external mucosal surfaces 
consists of gut-associated lymphoid tissue (GALT), the lymphoid structures 
associated with bronchoepithelium and lower respiratory tract (BALT), 
occular tissue, upper airway, salivary glands, tonsils and nasopharynx 
(NALT), larynx (LALT), middle ear cavity, male and female genital tracts, 
mammary glands, and the products of lactation . The organized lymphoid 
follicles in the GALT and BALT are considered the principal inductive sites 
of mucosal immune response (Staats, Jackson, Marinaro, Takahashi, Kiyono 
and McGhee, 1994). 
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2.8.1. Gut-associated lymphoid tissue (GALT) and Bronchoepithelium           
             associated lymphoid tissue (BALT)          
A substantial body of information has been generated with Peyer's 
patches and other organized lymphoid follicles in the GALT, including the 
appendix (Dasso and Howell, 1997), and the BALT concerning the 
induction of mucosal immune responses and the development of systemic 
hyporesponsiveness following oral exposure to an antigen (oral tolerance) 
(Javed, Gienapp, Cox and Whitacre, 1995 ). 
The common features of all inductive mucosal sites include an 
epithelial surface containing M cells (cells with microfold) overlying 
organized lymphoid follicles. Mucosal epithelium is a unique structure, and 
in addition to M cells, it contains mucin-producing glandular cells, 
lymphocytes, plasma cells, dendritic cells, and macrophages. The mucosal 
epithelial cells express polymeric immunoglobulin receptor (pIgR) and 
secretory component, major histocompatibility complex (MHC) class I and 
II molecules, other adhesion molecules, and a variety of cytokines and 
chemokines (McGhee et al., 1999). 
The dendritic cells are present in different components of the common 
mucosal immune system, including the organized lymphoid tissue and the 
mucosal epithelium. These cells can be strongly associated with potentiation 
of immune response and promote development of active immunity (Liu and 
MacPherson, 1993). Recent observations have suggested that dendritic cells 
are potent antigen-presenting cells (APC) and are critical in initiating 
primary immune responses, graft rejection, autoimmune disease, and 
generation of T-cell-dependent B-cell responses. The APC function is 
attributed in part to their ability to express co stimulatory molecules (CD80 
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and CD86) and other accessory ligands necessary for up regulation or 
induction of tolerance (Steinbrink, Wölfl, Jonuleit, Knop and Enk, 1997). 
2.8.2. Nasopharynx-associated lymphoid tissue (NALT).  
Recent studies in the rat, mouse, and hamster have shown the 
presence of organized lymphoid tissue at the entrance of the nasopharyngeal 
duct. This represents an important component of mucosal lymphoid tissue in 
the rodents (Small, Smith and Moss, 1985). The NALT appears to have 
better-developed lymphoid follicles, with marked intraepithelial infiltration 
by lymphocytes. The follicular areas are organized into B cells and 
intrafollicular (T-cell) areas of approximately similar size. The rodent NALT 
contains a wealth of dendritic cells. The lymphoid follicles are covered by 
ciliated epithelium containing few goblet cells and numerous M cells. The 
NALT M cells appear to be identical to those in Peyer's patches and BALT 
and are involved in similar immunological functions, including antigen 
uptake and subsequent mucosal immune responses to specific antigens 
(Sminia and Kraal, 1999). In humans, the nasopharyngeal lymphoid tissue is 
represented by the salivary glands and other glandular tissue in the 
Waldeyer's ring, which consists of paired palatine and tubal tonsils and 
unpaired pharyngeal and lingual tonsils. It is not clear how comparable the 
functional role of Waldeyer's ring in humans is to the NALT in rodents. 
However, there is increasing evidence to suggest that human tonsillar and 
adenoidal tissues are important components of mucosal immunity and 
function in a manner similar to those of GALT or BALT (Bernstein, Gorfien 
and Brandtzaeg, 1999). The tonsils consist of several lymphoid elements. 
These include follicular germinal centers, mantle zones of lymphoid 
follicles, the extrafollicular areas, and the reticular crypt epithelium on the 
surface in constant contact with the external environment. The tonsillar 
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epithelium contains a significant number of dendritic cells, M cells, memory 
B cells, and scattered B and T cells. The formation of the germinal center 
takes place shortly after birth, secondary to the activation by environmental 
antigens, and plasma cells appear in tonsils by 2 to 3 weeks of age. Unlike 
Peyer's patches, tonsils exhibit considerable in situ arise during T-cell-
dependent B-cell responses) generate plasma blasts and plasma cells of both 
IgG and IgA isotypes. 
There is, however, a predominance of IgG isotype (60 to 70% IgG versus 
15 to 20% IgA). The follicular germinal centers are often associated with 
clonal expansion of B cells, somatic hyper mutation in the B-cell 
immunoglobulin variable-region gene, positive selection of B cells, and 
eventual B-cell differentiation to memory cells and isotype-specific plasma 
cells (Bernstein et al., 1999).The tonsils, nasal and bronchial mucosa, and 
salivary glands exhibit similar distribution of IgA and IgD immunocytes. In 
addition, scattered areas in the crypt epithelium of nasopharyngeal tonsils 
(but not palatine tonsils) express secretary component. Another important 
feature of mucosal lymphoid tissue and the follicular germinal center is 
induction of the J-chain gene in some B-cell subsets. Tonsillar germinal 
centers express a very high percentage of extra follicular immunocytes with 
J-chain expression. More than 90% of these immunocytes are of the IgA 
isotype (Bernstein et al., 1999). 
2.9. Vaccination  
Long-term active memory is acquired following infection by activation of B 
and T cells. Active immunity can also be generated artificially, through 
vaccination. The principle behind vaccination is to stimulate the immune 
system and develop specific immunity against that particular pathogen 
without causing disease associated with that organism (Alberts et al., 2002).  
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Figure (1.1): M cells and the induction of mucosal immunity. 
 M cells are present in mucosal inductive sites in both the intestinal and 
upper respiratory tract, specifically in Peyer’s patches and the nasal-
associated lymphoid tissue, the tonsils and adenoids. M cells are thought to 
play an important role in antigen processing and possibly the induction of 
antigen-specific mucosal immunity in mucosal effector sites. Tissues 
followed by question marks are presumed sites since limited data are 
available on these tissues. 
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Figure (1.2): Differentiation and regulation of T-helper subsets and the 
immune response in the mucosal compartments.  
Encounter of pathogen- derived antigen or vaccine antigen will stimulate T-
helper cells to secrete cytokines. Depending on the stimulus, a Th1 or Th2 
cell response is induced. For example, intracellular pathogens will induce 
production of IL-12/IL-18 by macrophages, activating IFN-γð production by 
NK cells and inducing differentiation to a Th1- mediated immune response, 
which supports CMI and production of complement-fixing antibodies, 
presumably by production of cytokines such as IFN-γð, IL-2, and TNF-γð. A 
Th2 response can be observed upon infection with parasites or upon vaccine 
administration; this response is characterized by reduction of cytokines such 
as IL-4, IL-5, IL-6, IL- 10 and IL-13 which support humoral immunity. 
However, for induction of an S-IgA, TGF- ß ð1 is required to enable B-cells 
to switch to IgA. TGF- ßð1 production is associated with inhibition of IL-4 
production by Th2 cells inhibiting IgE production. 
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This deliberate induction of an immune response is successful because it 
exploits the natural specificity of the immune system, as well as its 
inducibility. With infectious diseases being the leading causes of death in the 
human population, vaccination represents the most effective manipulation of 
the immune system mankind has developed, (Janeway, 2005). Vaccine is  a 
product  which may  be suspension  of  living  or dead  cells ,or an antigenic 
fraction of cells, which when  injected  with or  without  adjuvant  enhances  
the immunity  production  in  the  animal’s  body (Bain, 1954). 
2.9.1. Mucosal vaccination 
The primary reason for using a mucosal route of immunization is that 
most infections affect or initiate the infectious process at the mucosal 
surfaces, and that in this infection, mucosal application of a vaccine is often 
required to induce a protective immune response (Holmgren and 
Czerkinsky, 2005). Advantage of mucosal vaccination is that this mode can 
induce both mucosal and systemic immune responses, which results in two 
layers of host protection against infectious diseases (O'Hagan, MacKichan 
and Singh, 2001). An effectively designed mucosal vaccine must: (1) protect 
from physical elimination and enzymatic digestion, (2) target mucosal 
inductive tissues including M cells, and (3) appropriately stimulate the 
innate immune system to generate effective adaptive immunity. In mucosal 
vaccine development, it is crucial to select the appropriate immunization 
route, and most current mucosal vaccine delivery is intended to mimic the 
natural encounter of mucosal inductive sites with environmental antigens 
and pathogens. Mucosal vaccination is usually performed by either oral 
(enteric) or intranasal (respiratory tract) application. In fact, many new 
vaccines are being tested by both routes to determine which induces immune 
responses via the CMIS most effectively. In many cases, intranasal 
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immunization is more effective and in general requires smaller vaccine 
doses with less adjuvant. Intranasal immunization has been shown to result 
in the development of antibody response in the mammary glands and in the 
genital tract (Conley and Delacroix, 1987). The occasional inefficiency of 
oral immunization is due in part to degradation of vaccine by the acidic 
gastric pH and proteolytic enzymes as well as by the potential for the 
induction of mucosally induced tolerance. In addition, a recent study by 
Glenn, (2000) provides a strong evidence that transcutaneous immunization 
is a simple and practical innovation that may improve the vaccine delivery. 
Mucosal immunization induces antigen-specific Th1- and/or Th2-type 
responses depending on the nature of the antigen, adjuvant and antigen 
delivery vehicle used. For example, administration of intracellular pathogens 
such as Salmonella led to the formation of Th1 cells producing IFN-γ, IL-2 
and TNF-β (Hess, Ladel, Miko and Kaufmann, 1996). Murine Th1-type 
immune responses are associated with the development of CMI and B-cell 
responses characterized by IgG2a synthesis. On the other hand, the use of 
cholera toxin (CT) as a mucosal adjuvant with soluble protein antigen 
induces antigen-specific Th2 cells producing IL-4, IL-5, IL-6, and IL-10. 
Among these Th2-type cytokines, IL-4 has been shown to switch µ heavy 
chain to certain γ subclasses (e.g., IgG1) and to e subclasses (e.g., IgE) 
(Rousset, Garcia, and Banchereau, 1991). Furthermore, Th2 type cells are 
considered to be the major helper phenotype for the support of IgA 
responses via the production of IL-5 and IL-6 in the mouse system. 
2.9.2. Types of vaccines  
2.9.2.1. Killed vaccines 
Are vaccines containing killed microorganisms. These are previously 
virulent micro-organisms that have been killed with chemicals or heat 
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(Wakefield, Murch, Anthony, Linnell, Casson, Malik, Berelowitz, Dhillon, 
Thomson, Harvey, Valentine, Davies and Walker-Smith, 1998). The 
antibody response against killed vaccines depends on the method of 
cultivation, way of preparation and killing, presence of adjuvants, degree of 
antigenic variation, route of administration and dose.  
2.9.2.2. Attenuated vaccines 
Attenuated live vaccines are prepared by passaging the organism in 
non–ordinary host or by growing it in unfavorable conditions. Attenuation  
trials of  HS  vaccine were  achieved by passage in pigeons .The use of live 
attenuated  pasteurella  organisms  as vaccine  to prevent the disease  caused 
by p.multocida  was reported by Bierer, (1969).  
2.9.2.3. Toxoid vaccines  
A toxoid is an inactivated toxin, the harmful substance produced by a 
microbe. Toxoid vaccine was proved useful against atrophic rhinitis caused 
or associated with toxigenic strain of P.multocida (Bording and Riising, 
1986).  
2.10. Adjuvants 
The word adjuvant is derived from the Latin word adjuvare, which 
means help or aid or to enhance (Vogel, 1998). Singh and O'Hagan (2003) 
stated that immunological adjuvants were originally described by Ramon in 
1924 as “substances used in combination with a specific antigen that 
produced a more robust immune response than the antigen alone”. This 
broad definition encompasses a very wide range of materials (Vogel and 
Powell, 1995). The first adjuvants were developed in the 1920’s and a 
number of substances including chemicals, microbial components and 
mammalian proteins have been used to boost the immunity (Cox and 
Coulter, 1992; 1997). 
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Adjuvants are structurally heterogeneous compounds that enhance or 
modulate the immunogenicity of the poorly immunogenic vaccine proteins 
or peptides (Gupta, Relyveld, Lindblad, Bizzini, Ben-Efraim and Gupta, 
1993). Most vaccines traditionally consist of live attenuated pathogens, 
whole inactivated/killed organisms or inactivated toxins containing many 
immunopotentiators essential for activating integrated protective immune 
responses. An adjuvant can be used for increasing the immunogenicity of 
poor antigen, improving the efficacy of vaccine in new born and reducing 
the amount of antigen or the number of immunizations (McElrath, 1995). 
Compared to injection of antigen alone, injection of antigen plus an adjuvant 
generally permits use of a much smaller quantity of the antigen and greatly 
enhances the antibody titer (Kaeberle, 1986).  
2.10.1. Roles of adjuvants in modulation of immune responses 
Adjuvants can be used to improve the immune response to vaccine 
antigens for several different purposes, including: (1) increasing the 
immunogenicity of weak antigens; (2) enhancing the speed and duration of 
the immune response; (3) modulating antibody avidity, specificity, isotype 
or subclass distribution; (4) stimulating cell mediated immunity; (5) 
promoting the induction of mucosal immunity; (6) enhancing immune 
responses in immunologically immature or senescent individuals; (7) 
decreasing the dose of antigen in the vaccine to reduce costs or (8) helping 
to overcome antigen competition in combination vaccines (Singh and 
O’Hagan, 2003). Adjuvants were initially thought of as agents capable of 
promoting and sustaining antibody response. However, new evidence has 
shown that adjuvants influence the titer, duration, isotype and avidity of 
antibody, and affect the properties of cell-mediated immunity (Hunter, Olsen 
and Bennett, 1995). 
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2.10.2. Classification of adjuvants 
Different scientists used different criteria for classifying the adjuvants. 
Cox and Coulter (1992) classified adjuvants into particulate and non-
particulate groups. According to Vogel (1998) adjuvants can be classified 
according to their sources, mechanism of action or physiochemical 
properties. (Edelman, 1997; reviewed by Allison and Byars (1991)) 
classified adjuvants into three groups: (1) immunostimulatory adjuvants, (2) 
carrier adjuvants and (3) vehicle adjuvants. Adjuvants are also classified: (1) 
according to their route of administration like mucosal or parental routes; (2) 
divided into alum salts and other mineral adjuvants, tensoactive agents, 
bacterial derivatives, vehicles and slow release materials or cytokines (Byars 
and Allison, 1990). (3) Divided into the groups: gel-based adjuvants, 
tensoactive agents, bacterial products, oil emulsions, particulate adjuvants, 
fusion proteins or lipopeptides (Jennings, Simms and Heath, 1998). 
Mostly aluminum or oil adjuvants are used in vaccine, but these 
chemical adjuvants that have many disadvantages, such as side effects, 
strong local stimulation and carcinogenesis, together with complicated 
preparations or failure to increase immunogenicity of weak antigen,  
(Bowersock and Martin, 1999). Comparative studies in humans and animals 
showed that aluminum is a weak adjuvant for antibody induction to 
recombinant protein vaccines and induces a Th2, rather than a Th1 response 
(Gupta, 1998). Some other groups of adjuvants including oil emulsions, 
lipopolysaccharides, polymers, saponins, liposomes, cytokines, ISCOMs, 
Freund’s complete adjuvant, Freund’s incomplete adjuvant, alums, bacterial 
toxins etc., have been evaluated, although the mechanism of action of 
adjuvants often remain poorly understood (Edelman, 1997). 
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2.10.3. Mucosal Adjuvants 
Adjuvant has a complex mechanism of action as an immunostmulator, 
delaying the absorption of vaccine and prolonging the antigenic stimulus to 
the antibody forming cells. A number of chemical agents have been tested to 
enhance the immunogenicity of mucosally administered antigens (especially 
for nonreplicating antigens), including cholera toxin (CT) holotoxin (B 
subunit), E. coli heat-labile toxin, lectins and polyelectrolytes, ISCOM, 
actins, avridine, low-oil emulsion (MF59), lipid A, lysophosphatidyl 
glycerol, and cytokines (IL-5). Such antigens in general induce only weak or 
insufficient immune responses when administered mucosally. Adjuvants 
influence virtually every aspect of immune response to an antigen (Elson and 
Dertzbaugh, 1999). 
2.10.3.1. Olive Oil 
       Olive oil contains triacylglycerols and small quantities of free fatty 
acids, glycerol, pigments, aroma compounds, sterols, tocopherols, phenols, 
unidentified resinous components (Kiritsakis, 1998) 
2.10.3.1.1. Oleic acid 
       Olive oil contains a high percentage of monounsaturated oleic acid. 
Thus, it is natural monounsaturated oil. This particular fatty acid reduces 
LDL-cholesterol, which is responsible for the formation of the 
atherosclerotic plaque, and increases the HD-cholesterol. Hydrocarbon 
squalene: The hydrocarbon squalene, an important metabolic factor, is 
present in high percentages in olive oil.  
2.10.3.1.2. Phenolic compounds 
        Olive fruit contains simple and complex phenolic compounds. Most of 
these compounds pass into the oil increase its oxidative ability and improve 
its taste. Hydrohytyrosol, tyrosol and some phenolic acids are mainly found 
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in olive oil (Kiritsakis, 1998). The phenol content and the specific 
composition of these phenols in olive oil depend on the altitude where the 
olive trees are grown, on the harvesting time and on the processing 
conditions (Cinquanta, Esti and Notte, 1997; Kiritsakis, 1998).                                                
2.10.3.1.3. Tocopherols                                                                                 
        Olive oil contains the tocopherols α-, β-, γ-, δ- (α-tocopherol covers 
almost 88%). The tocopherol content of olive oil depends not only on the 
presence of these compounds in olive fruit but also on several other factors 
involved in the transportation, storage and olive fruit processing. According 
to Viola (1997), the ratio of vitamin-E to polyunsaturated fatty acids in olive 
oil is better than to other edible oils.                                      
2.10.3.2. Sesame oil                                                                                       
Sesame (Sesamum indicum L., Pedaliaceae) is a very old cultivated 
crop and thought to have originated in Africa (Ram, Catlin, Romero and 
Cowley 1990). Sesame oil is fixed oil obtained by expression from the seed 
of Sesamum indicum L. It is a pale-yellow liquid with a slight, pleasant 
odour and a bland taste, it does not solidify when cooled to 0 °C. Sesame oil 
consists of glycerides, fatty acids such as oleic and linoleic acids, with small 
proportions of stearic, palmitic and arachidic acids. It also contains about 1% 
of sesamin, and a smaller amount of sesamolin. Sesame oil is slightly 
soluble in alcohol, miscible with ether, chloroform and light petroleum. And 
can be sterilized by dry heat. Chlorosesamone obtained from roots of sesame 
has antifungal activity (Begum, Furumot and Fukui, 2000). Sesame lignans 
have antioxidant and health promoting activities. High amounts of both 
sesamin and sesamolin have been identified in sesame (Sirato-Yasumoto, 
Katsuta, Okuyama, Takahashi and Ide, 2001). Both sesamin and sesamolin 
were reported to increase both the hepatic mitochondrial and the 
 31
peroxisomal fatty acid oxidation rate. Sesame seed consumption appears to 
increase plasma gamma-tocopherol and enhanced vitamin E activity which 
is believed to prevent cancer and heart disease (Cooney, Custer, Okinaka 
and Franke, 2001). Sesame has an antibacterial effect as was proven by Acar 
and Goldstein (1991), using the disk diffusion method. Sesame oil is a 
pharmaceutic aid used as a solvent for intramuscular injections (Tyler, Brady 
and Robbers, 1976). The oil was used during the 4th century by the Chinese 
as a remedy for toothaches and gum disease. Sesame oil is known to reduce 
cholesterol due to the high polyunsaturated fat content in it. Other uses of 
sesame oil include the treatment of blurred vision, dizziness, and headaches. 
The Indians have used sesame oil as an antibacterial mouthwash (Annussek, 
2001). A recent clinical trial proved that sesame oil was significantly 
effective for treating dryness of nasal mucosa (Johnson, Bratt, Michel-
Barron, Glennow and Petruson, 2001). 
2.10.3.3. Vitamin D3 (Vit D3) 
        It was first demonstrated in mice by Enioutina, Visic and Daynes, 
(2000) that an intramuscular, subcutaneous or intradermal  immunization 
with a microbial antigen and aluminium hydroxide as an adjuvant induces a 
mucosal immune response when 1α, 25(OH) 2D3 (Vit D3, calcitriol), the 
active metabolite of vitamin D, is added as an additional immunomodulator. 
Mice showed enhanced antigen-specific IgG and IgA in serum and all tested 
mucosal secretions (tears, oral, vaginal and colorectal secretions) (Daynes, 
Enioutina, Butler, Mu, McGee and Araneo, 1996) and increased numbers of 
IgA and IgG secreting cells (ASC) in systemic (the local draining lymph 
node and spleen) and mucosa-associated lymphoid tissues (Peyer’s patches, 
mesenteric lymph nodes). Vit D3 modulated the production of cytokines in 
the local draining lymph node. When cells from the local draining lymph 
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node of a mouse treated with Vit D3 were stimulated in vitro with anti-CD3€ 
an enhanced production of IL-4, IL-5 and IL-10 (Th2-cytokines) and a 
reduced production of IL-2 and IFN-γ Th1-cytokines) was seen (Daynes et 
al, 1996). So, in the local draining lymph node, a switch towards a Th2-
cytokine profile occurred, as is necessary for an IgA response. Furthermore, 
migration of antigen- pulsed dendritic cells from the local draining lymph 
nodes towards the Peyer's patches was seen, where the activation and 
differentiation of antigen-specific B cells for a mucosal immune response is 
initiated (Enioutina et al., 2000). Vit D3 exerts its effects on the immune 
system by binding to a nuclear receptor (nVDR), which is present in 
activated Th, cytotoxic T cells (CTL) as well as in activated B cells (Baran 
and Sorensen, 1994) via this receptor, Vit D3 modulates the production of 
cytokines (Lemire, Adam, Sakai and Jordan, 1984). By reducing the 
transcription and secretion of among others IFN-γ, IL-2, IL-8, IL-12 and 
GM-CSF. IL-12 is the most important cytokine for promoting differentiation 
of Th0 cells towards Th1 cells. Furthermore, Vit D3 favours the induction of 
D4+CD25+ regulatory T cells and enhances the production of Th2 cytokines 
such as IL-4 and IL-10, which in turn inhibits Th1 responses. Vit D3 is also 
known to stimulate TGF-ß that is involved in mucosal immunity, isotype 
switching towards IgA as well as IgG2b.               
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CHAPTER TWO 
MATERIALS AND METHODS 
3.1. Haemorrhagic septicemias (HS) vaccine  
HS vaccine was donated by the Central Veterinary Research 
Laboratories, Soba, (without adjuvant). Vaccine was produced in the 
Gottingen bioreactor (fermenter) under the optimized physical growth 
condition temperature at 37ºC, pH 7.4 and stirring ×300 rpm and contained 
109 cfu/ml.  All production steps of the vaccine were performed under strict 
aseptic condition, as was reported by Elbashir, (1993). 
3.2. Preparation of whole cell lysate 
The Isolate of P.multocida 222 sero type B6 was obtained from the 
freeze-dried stock of the Department of Microbiology, Faculty of Veterinary 
Medicine, University of Khartoum. The isolate was reconstituted in nutrient 
broth and incubated at 37°C for 24 hours. Growth was checked and tested 
for purity and the culture was kept in cooked meat medium for preparation 
of whole cell lysate. 
Pasteurella multocida serotype B 6 was grown in nutrient broth for 48 
hour at 37°C. One liter culture was harvested by centrifugation at ×4000 rpm 
for 20 minutes at 4°C (Megafuge 1.0R, Germany) and the packed cellular 
mass was washed three times with phosphate buffer saline pH 7.2. The cells 
were then resuspended in the same buffer and subjected to ultrasonic 
disruption (sonnicator) (MSE-England) at ×18000rpm for 10 minutes at 
short intervals at 4°C (Mortenson, Valentine and Carnhan, 1962). Cell debris 
and unbroken cells were removed by centrifugation at 3000 rpm for 15 
minutes and the supernatant was stored frozen until used. 
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3.3. Laboratory animals 
3.3.1. Rats  
Forty eight rats were kept in conventional animal house at the 
Department of Microbiology, allowed to adapt to food and water and later 
divided into five groups (1-5). Groups 1, 2 and 3 were further divided into 
sub groups (a) and (b) each containing 6 rats. Groups 4 and 5 were control 
groups of 6 rats each. 
3.4. Bacteriological media 
Are prepared according to the manufacturer’s recommendations. 
3.4.1. Blood agar 
This medium is composed of nutrient agar, which consists of: 
Lab-lemco powder                                    1 g 
Yeast extracts                                            2 g 
Peptone                                                     5 g 
Sodium chloride                                       5 g 
Agar                                                        15 g        
Preparation 
One liter was prepared as described by Barrow and Feltham (2003). 
Forty grams of blood agar base No.2 were suspended in 950 ml of distilled 
water, pH was adjusted to 7.4 and then sterilized by autoclaving at 121°C for 
15 minutes. Fifty milliliters of defibrinated blood were added after cooling 
to 50°C and mixed. The complete medium was poured into sterile Petri 
dishes and left to solidify at room temperature on leveled surface. 
3.4.2. Nutrient broth  
Lab-lemco powder                                    1 g 
Yeast extracts                                            2 g 
Peptone                                                     5 g 
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Sodium chloride                                       5 g 
Preparation 
It was prepared according to Barrow and Feltham (2003) by 
dissolving 13 grams of the medium in one liter of distilled water. The pH of 
the medium was adjusted to 7.4 and was distributed into screw capped 
bottles 5 ml each and sterilized by autoclaving at121°C for 15 minutes. 
3.4.3. Robertson’s cooked meat medium 
The medium was prepared according to Barrow and Feltham (2003). 
It consists of 1000 grams of minced meat and 1000 ml of o.o5 N-NaOH. The 
minced meat was added to the alkali solution, mixed well then heated to 
boiling and simmered for 20 minutes with frequent stirring. The fat was 
skimmed off and the pH was adjusted to 7.5. The liquid part was strained 
through muslin and excess liquid was squeezed out.  
Meat particles were dried at a temperature below 50°C, then sufficient 
dried meat was placed in screw capped container to depth of about 2.5 cm. A 
sufficient nutrient broth was added then sterilized by autoclave at 115°C for 
20 minutes.    
3.5. Solutions 
3.5.1. Phosphate buffer saline (PBS) 
Sodium chloride                                                 8 g 
 Potassium chloride                                          0.2g 
Disoduim hydrogen phosphate                     1.15 g  
 Potassium dihydrogen phosphate                  0.2 g 
Preparation 
These buffers were dissolved at 1liter of distilled water, pH 7.2 and 
autoclaved for 15 minutes at 121°C and allowed to cool at room 
temperature. 
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3.5.2. Normal saline 
  It was prepared by dissolving 8.5g NaCl in one liter of distilled water 
and autoclaving at 121°C for 15 minutes. 
3.5.3. Borate-succinate buffer  
Consist of solution A (Sodium tetraborate (19.0g/l)), solution B 
(succinic acid (5.9g/l)), Sodium chloride and horse serum. Solution B was 
added to one liter of solution A until pH 7.5 was reached. Then 0.14 NaCl 
and heat inactivated 1% horse serum were added.  
 3.5.4. Alsever’s solution 
Glucose                                                        20 g  
Sodium citrate                                             4.2 g  
Trisodium citrate                                         8.0 g 
 Citric acid                                                 0.55 g 
 Distilled water                                        1000 ml 
Preparation 
 These were mixed and autoclaved at 115˚C or 15 min. 
3.6. Mucosal adjuvants 
Olive oil, sesame oil were included as mucosal adjuvants in this study 
whereas vitamin D3 was used as safe mucosal adjuvant as was reported by 
(Daynes, et al., 1996). 
3.6.1. Preparation of Mucosal adjuvant vaccine 
The national HS vaccine was mixed with each mucosal adjuvant in 
the ratio: 1:1 to contain 5×108 cfu/ml and the ratio 2:1 to contain 3.3×108 
cfu/ml. The preparation was administered intranasally and all rats received a 
booster dose on day 15 post initial inoculation. A control group received 
phosphate buffered saline and another control group received vaccine alone, 
as is shown in table (2.1). 
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3.7. Immunization of rats 
3.7.1. Group 1 
In this group, olive oil was used as mucosal adjuvant. Rats were 
divided into two sub groups, G1 (a) and G1 (b), each consisted of 6 rats. G1 
(a) were immunized intranasaly with 30µl of 1:1 vaccine adjuvant mixture 
and boostered with 20µl 2 weeks post-initial vaccination. Rats in G1 (b) 
were immunized intranasaly with 30µl of 2:1 vaccine adjuvant mixture and 
boostered with 20µl of the same preparation at day 15 post-initial 
vaccination. 
3.7.2. Group 2 
In this group, sesame oil was used as mucosal adjuvant. Rats were 
divided into two subgroups, G2 (a) and G2 (b), each consisted of 6 rats. G2 
(a) were immunized intranasaly with 30µl of 1:1 vaccine adjuvant mixture 
and boostered with 20µl 2weeks post-initial vaccination. Rats in G2 (b) were 
immunized intranasaly with 30µl of 2:1 vaccine adjuvant mixture and 
boostered with 20µl of the same preparation at day 15 post-initial 
vaccination.  
3.7.3. Group 3 
In this group, vitamin D3 was used as mucosal adjuvant. Rats were 
divided into two sub groups, G3 (a) and G3 (b), each consisted of 6 rats. G3 
(a) were immunized intranasaly with 30µl of 1:1 vaccine adjuvant mixture 
and boostered with 20µl 2 weeks post-initial vaccination. Rats in G3 (b) 
were immunized intranasaly with 30µl of 2:1 vaccine adjuvant mixture and 
boostered with 20µl of the same preparation at day 15 post-initial 
vaccination. 
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3.7.4. Group 4 
In this group, six rats were immunized intranasaly with 30µl of the 
national Hemorrhagic septicemia (HS) vaccine without adjuvant and 
boostered intranasaly with 20µl of the vaccine 2 week after the initial dose. 
3.7.5. Group 5 
In this group, six rats were immunized intranasaly with 30µl of sterile 
Phosphate buffered saline (PBS) alone, boostered intranasaly with 20µl of 
the sterile PBS on day 15.  
3.8. Tracheobronchial Lavage 
Rats in each group were killed one week after second immunization ie on 
day 21. Animals were dissected, respiratory tracts (lung, trachea) were 
removed, and the trachea and bronchial tree were washed with 5ml PBS 
each in petri-dishes. The respiratory-lavage was transferred into test tubes 
and centerifugated at ×1000 rpm (MSE, BRITAIN) for 15 minutes the 
supernatants were collected and kept at -20 ºC until used. 
 3.9. Serological tests 
    The immunodiffution test and passive haemagglutination test were used 
to determine the presence of P.multocida antibodies in lung lavage. Positive 
and negative control TB lavages were included in each test.  
3.9.1. Agar gel diffusion test 
This test is prepared after the method described by Beard (1970). 
 3.9.1.1. Preparation of agar gel 
       A weight of 1 gram of agarose and 0.8 gram of sodium chloride (NaCl) 
were added to 100 ml of deionized distilled water (D.D.W) in flask. The 
mixture was then boiled in microwave for 2 min until it become clear. A 
volume of 0.5 ml phenol was then added as preservative. The gel was 
distributed in 20 ml amounts in plates and after solidification at room 
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temperature on a leveling table, the plates were kept in the refrigerator at 4ºC 
until used. 
 3.9.1.2. Test procedure 
       A rosette of six peripheral wells and central well were cut in the agar 
with template and agar plugs were removed with a Pasteur pipette. The 
central well was filled with 50µl whole cell lysate using micropipette 
(Antigen was mixed with 1% sodium Dodecyle sulphate (SDS)), while the 
peripheral wells were filled with 50µl the the tracheobronchial  lavage. The 
plates were then covered and incubated at room temperature in humid 
chamber and examined daily for the development of precipitation lines. 
Positive results plates were then washed with NS, dried at 56 °C for 3 days, 
stained with Commassie blue for better visualization and pictured.  
3.9.2. Indirect haemagglutination test 
3.9.2.1. Tanning erythrocytes 
       Sheep erythrocytes (SRBCs) in Alsever’s solution were washed three 
times in saline at 300×g for 10 min. SRBCs suspension was adjusted to 4% 
v/v in phosphate-saline buffer pH 7.5. Then 2.5 mg of tannic acid was added 
to 50 ml of phosphate buffer saline and mixed with 50 ml of 4% SRBC 
suspention. The mixture was incubated at 37˚C for 15 minutes. The cells 
were centrifuged very gently at 100×g for 20 min. Cells were divided into 
two aliquots, each was washed with phosphate buffered saline at 100×g for 
20 min. One volume of the cells was used for coating of RBCs with antigen 
and the other as control cells. The cells were re-suspended in 50 ml PBS and 
50 ml of the P.multocida whole cell antigen were added (2 mg /ml initial 
concentration) and incubated at 37˚C for 30 minutes and then washed in 
PBS by centrifugation and re-suspended in 100 ml of boarate-succinate 
buffer. The second aliquot of cells was re-suspended in 100 ml of boarate-  
 40
Table (2.1): Vaccination regiment of the various groups 
 
Booster dose
day 15  
Initial dose 
Day one  
Vaccine 
adjuvant 
ratio 
Adjuvant  Group 
20µl 
20µl 
30µl 
30µl 
1:1a 
2:1b 
Olive oil G1a 
G1b 
20µl 
20µl 
30µl 
30µl 
1:1a 
2:1b 
Sesame oil G2a 
G2b 
20µl 
20µl 
30µl 
30µl 
1:1a 
2:1b 
Vitamin D3 G3a 
G3b 
20µl 30µl 109cfu/ml – G4 
20µl  30µl – – G5 
 
Key: 
a = 5×108 cfu 
b = 3.3×108 cfu 
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succinate buffer. The uncoated cells were used as control cells in the assay. 
Formalin was added to both cell suspensions to give final concentration of 
0.2% formalin as a preservative. The formalin was added drop by drop 
during 20-30 min. Cells were left to settle for 24 hrs at 4°C and the 
supernatant were poured off and re-suspended in boarate-succinate buffer. 
The cells were allowed to settle for 24 hrs and washed again in boarate-
succinate buffer. Cell suspensions were adjusted to 1% v/v. 
3.9.2.2. Indirect haemagglutination test procedure  
The test was performed according to Hudson and Hay (1980): Starting 
dilution was prepared in test tubes prior to the test using 10µl of 
tracheobronchial lavage diluted in 1,990µl of PBS to give final dilution of 
1/200. The test was performed in v-shaped microtiter plates. Each well in 
microtiter plates contains 50 µl of PBS, each tracheobronchial lavage sample 
was two fold diluted across each row. To all wells were added with 50µl of 
antigen-adsorbed/sensitized red blood cells (RBCs). Positive, negative 
control lavages were included for each test run. Haemagglutination was 
detected by observing the presence or absence of tear-shaped streaming of 
RBCs. 
3.10. Statistical analysis 
       Data was entered in and analyzed using the SAS program JMP version 
7.0. Numerical data were presented as means and standard deviation. The 
significance of the mean difference between two independent groups was 
determined using Students' sample t test or one-way ANOVA (or ANOVA 
with Multiple comparisons) when comparing more than two groups. 
Dunnett's test was used when comparing several groups to a control group, 
with a p value of ≤0.05 considered statistically significant. 
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CHAPTER THREE 
RESULTS 
4.1. Indirec haemagglutination tests 
4.1.1. Group (1)  
Tracheobronchial (TB) lavages from immunized rats were tested for 
the presence of mucosal specific P.multocida antibodies by indirect 
heamagglutination IHA test and their titers are shown in table (3.1, 3.2). The 
titers of Abs for sub-group 1(a), that receive olive oil vaccine mixture 1:1, 
ranged between 0.256×105 to 2.048×105, while for sub-group 1(b), in which 
the HS vaccine and olive oil were mixed in 2:1 ratio the titers were between 
0.512×105 to 2.048×105 as shown in fig (3.1) and fig (3.2). These titers were 
statistically (P= 0.0082) significant when compared with group 4 as depicted 
in fig (3.3). 
4.1.2. Group (2) 
The indirect heamagglutination test for the presence of specific P. 
multocida antibodies in TB lavage in sub-group 2(a) of rats immunized 
intranasally with HS vaccine in sesame oil in 1:1 ratio, revealed mean IHA 
antibody titer equal to 20.48×105, whereas sub-group 2(b), immunized with 
HS vaccine in sesame oil in 2:1 ratio, their mean IHA titer was 5.12×105 as 
shown in table (3.1, 3.2) and their fig (3.4) and (3.5). These Ab titers of sub-
group 2(a) were statistically (P=0.0227) significant when compared with 
group (4) as depicted in fig (3.6). 
4.1.3. Group (3) 
 Indirect haemagglutination Ab titers for TB lavage of rats in group 
(3) immunized with HS vaccine in vitamin D3 in 1:1 and 2:1 ratio were 
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shown in table (3.1). In sub-group 3 (a), the titer of Abs ranged between 
2.56×105 and 20.48×105, whereas in sub-group 3(b) the Ab titers ranged 
between 2.56×105-10.24×105  as shown in table (3.1, 3.2), and in fig (3.7, 3.8 
and 3.9). These Abs titers of sub-group 3(a) are statistically (P=0.0272) 
significant when compared with group (4) as depicted in fig (3.9). 
4.1.4. Group (4)   
Tracheobronchial lavages from this group were tested for the presence 
of mucosal antibodies using indirect haemagglutination test. In rats that were 
immunized with HS vaccine alone, the titer of Abs were ranged between 
2.56×105 to 5.12 ×105 as depicted in table (3.1, 3.2) and fig (3.10). These 
Abs titer values were lower than in the other groups immunized with 
adjuvants as shown in fig (3.9) and (3.12) and table (3.3) and (3.4). 
4.1.5. Group (5) 
As demonstrated in table (5), the results of indirect haemagglutination 
test for lungs lavage of rats immunized with PBS as control group, were 
found to be negative for Abs as shown in fig (3.1), (3.2), (3.4), (3.5), (3.7), 
(3.8), (3.10) and (3.11). 
4.1.6. The effect of vaccine adjuvant ratio on Ab titer    
Vaccine adjuvant ratio 1:1 gave high Ab titer when sesame oil and 
vitamin D3 were used as mucosal adjuvants, whereas vaccine adjuvant ratio 
2:1 gave high Ab titer when only olive oil was used as mucosal adjuvant as 
shown in table (3.2, 3.6) and fig (3.13). The vaccine without an adjuvant 
gave low Ab titer as shown in table (3.2), (3.4), (3.5) and (3.6). 
4.2. Agar gel diffusion test 
Tracheobronchial lavages from immunized rats were tested for the 
presence of mucosal specific P.multocida antibodies by agar gel diffusion 
test. Tracheobronchial lavage of all groups were found positive for the 
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presence of antibodies specific for P.multocida whole cell lysate Ag by 
forming sharp precipitation lines as shown in figure (3.15). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 45
Table (3.1): Reciprocal of IHA titer for tracheobronchial lavage of the 
individual rat in various groups ×104  
 
Group Titer of Abs Mean Standard 
deviation
1 (a) 10.24 
 
5.12 
 
2.56 
 
20.48 
 
10.24 
 
10.24 
 
9.81 
 
6.15 
1 (b) 5.12 20.48 10.24 20.48 20.48 10.24 14.51 6.81 
2 (a) 2.56 
 
10.24 
 
20.48 
 
5.12 
 
20.48 
 
20.48 
 
13.23 
 
8.32 
2 (b) 5.12 
 
2.56 
 
2.56 
 
1.28 
 
1.28 
 
1.28 
 
2.35 
 
1.50 
3 (a) 20.48 
 
10.24 
 
5.12 
 
20.48 
 
10.24 
 
2.56 
 
11.52 
 
7.55 
3 (b) 5.12 
 
5.12 
 
5.12 
 
5.12 
 
10.24 
 
2.56 5.55 
 
2.52 
4 2.56 
 
5.12 
 
2.56 
 
5.12 
 
2.56 
 
2.56 
 
3.41 
 
1.32 
5 _ _ _ _ _ _ _ _ 
 
Table (3.2): Effect of vaccine adjuvant ratio on Abs titer ×104  
  
Adjuvant Group (a)¹ Group (b)² 
Olive oil 9.81± 6.15 
 
14.51± 6.81 
Sesame oil 13.23± 8.32 
 
2.35± 1.50 
 
Vitamin D3 11.52± 7.55 
 
5.55± 2.52 
 
Plain vaccine 3.14±1.32 _ 
   
Titer of Abs: mean ± standard deviation 
1– Vaccine adjuvant ratio was 1:1 
2– Vaccine adjuvant ratio was 2:1 
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Fig (3.1):  Reciprocal of IHA titers of tracheobronchial lavage obtained 
from individual rat in group 1(a) 
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–Six rats were immunized with HS vaccine in olive oil in the ratio 1:1, 
induced is not statistically significant Ab titer (P= 0.2235). 
–P <0.05 is significant.    
–Average ± SD of IHA titer of six rats in G4 that received plain HS vaccine 
(without an adjuvant–adjuvant control). 
–Rats in G5 were non-immunized. 
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Fig (3.2):  Reciprocal of IHA titers of tracheobronchial lavage obtained 
from individual rat in group 1(b) 
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–Six rats were immunized with HS vaccine in olive oil in the ratio 2:1, 
induced a significant Ab titer (P= 0.0082). 
–P <0.05 is significant.    
–Average ± SD of IHA titer of six rats in G4 that received plain HS vaccine 
(without an adjuvant–adjuvant control). 
–Rats in G5 were nonimmunized. 
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Fig (3.3): Comparison of mean IHA titer of G1 (vaccine with olive oil) 
and G4 (vaccine only) 
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Fig (3.4):  Reciprocal of IHA titers of tracheobronchial lavage obtained 
from individual rat in group 2(a) 
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–Six rats were immunized with HS vaccine in sesame oil in the ratio 1:1, 
induced a significant Ab titer (P= 0.0227). 
–P <0.05 is significant.    
–Average ± SD of IHA titer of six rats in G4 that received plain HS vaccine 
(without an adjuvant–adjuvant control). 
–Rats in G5 were nonimmunized. 
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Fig (3.5):  Reciprocal of IHA titers of tracheobronchial lavage obtained 
from individual rat in group 2(b) 
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–Six rats were immunized with HS vaccine in sesame oil in the ratio 2:1, Ab 
titer induced is not statistically significant (P= 0.9991). 
–P <0.05 is significant.    
–Average ± SD of IHA titer of six rats in G4 that received plain HS vaccine 
(without an adjuvant–adjuvant control). 
–Rats in G5 were nonimmunized. 
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Fig (3.6): Comparison of mean IHA titer of G2 (vaccine with sesame oil) 
and G4 (vaccine only) 
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Fig (3.7):  Reciprocal of IHA titers of tracheobronchial lavage obtained 
from individual rat in group 3(a) 
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–Six rats were immunized with HS vaccine in vitamin D3 in the ratio 1:1, 
induced a significant Ab titer (P= 0.0272). 
–P <0.05 is significant.    
–Average ± SD of IHA titer of six rats in G4 that received plain HS vaccine 
(without an adjuvant–adjuvant control). 
–Rats in G5 were nonimmunized. 
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Fig (3.8):  Reciprocal of IHA titers of tracheobronchial lavage obtained 
from individual rat in group 3(b)  
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–Six rats were immunized with HS vaccine in vitamin D3 in the ratio 2:1, Ab 
titer induced is not statistically significant (P= 0.9661). 
–P <0.05 is significant.    
–Average ± SD of IHA titer of six rats in G4 that received plain HS vaccine 
(without an adjuvant–adjuvant control). 
–Rats in G5 were nonimmunized. 
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Fig (3.9): Comparison of mean IHA titers of G3 (vaccine with vitamin 
D3) and G4 (vaccine only) 
 
11.5
5.5
3.4
0
5
10
15
20
25
G-3(a) G-3(b) G-4
Experimental Groups
 T
B 
la
va
ge
 IH
A
 T
ite
rs
 (X
10
 )
Lower 95% CI
Mean
Upper 95% CI
4
 
 
 
 
 
 
 
 
 
 
 
 
 
 55
Fig (3.10):  Reciprocal of IHA titers of tracheobronchial lavage obtained 
from individual rat in group 4 
 
0
5
10
15
20
25
1 2 3 4 5 6 G 4 G 5
Individual rat
Abs titers ×104 
 
 
 
–Six rats were immunized with HS vaccine alone. 
–Average ± SD of IHA titer of six rats in G4 that received plain HS vaccine 
(without an adjuvant–adjuvant control). 
–Rats in G5 were non-immunized. 
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Fig (3.11): Reciprocal of IHA titers for tracheobronchial lavage in 
various groups 
 
 
 
 
 
– Bar ±SD represent mean ± SD. 
– Ab titers were significant in group: G1a, G1b, G2a and G3b. 
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4.3. Visual Comparison of Group Means 
Each multiple comparison test begins with a comparison circles plot, 
which is a visual representation of group mean and 95% Confidence Interval 
comparisons. The plot follows with a reveal table of the comparisons.  
Overlap marks show for each diamond and are computed as (group 
mean ± CI). Overlap marks in one diamond that are closer to the mean of 
another diamond than that diamond's overlap marks indicate that those two 
groups are not different at the 95% confidence level. You can compare each 
pair of group means visually by examining how the comparison circles 
intersect. The outside angle of intersection tells you whether group means 
are significantly different. Circles for means that are significantly different 
either do not intersect or intersect slightly so that the outside angle of 
intersection is less than 90 degrees. If the circles intersect by an angle of 
more than 90 degrees or if they are nested, the means are not significantly 
different. If the intersection angle is close to 90 degrees, you can verify 
whether the means are significantly different by clicking on the comparison 
circle to highlight it. The highlighted circle appears with a thick solid line. 
Red circles representing means that are not significantly different from the 
highlighted circle show with thin lines. Circles representing means that are 
significantly different show with a thick gray pattern. 
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Fig (3.12): Visual comparison of mean and 95% CI of IHA titer (×104) 
among all rat groups 
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G-1(a): Vaccine + Olive Oil (1:1), G-1(b): Vaccine + Olive Oil (2:1), G-2(a): Vaccine + 
Sesame Oil (1:1), G-2(b): Vaccine + Sesame Oil (2:1), G-3(a): Vaccine + Vitamin D3 
(1:1), G-3(b): Vaccine + Vitamin D3 (2:1). 
(F ratio=4.5, p value=0.001, statistically significant) 
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Fig (3.13): Effect of vaccine-adjuvant ratio on IHA titres of P. multocida 
in immunized rats. 
 Reciprocal of IHA titers for tracheobronchial lavage 
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Comparison of mean and 95% CI of tracheobronchial lavage IHA titers 
among the experimental groups.  
(Statistically significant, p=0.001) 
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Table (3.3): Means and 95% CI for One-way ANOVA test 
 
95% Confidence Interval  
Experimental Group 
 
Mean Lower Bound Upper Bound 
G-1(a) 9.81 5.48 14.15 
G-1(b) 14.51 10.17 18.84 
G-2(a) 13.23 8.89 17.56 
G-2(b) 2.35 -1.99 6.68 
G-3(a) 11.52 7.19 15.85 
G-3(b) 5.55 1.21 9.88 
G-4 3.41 -0.92 7.75 
 
 
Table (3.4): Comparison of each group with the control group using 
Dunnett's method 
 
Control Group Experimental Group p-Value
G-4 G-1(b) 0.0082* 
 G-2(a) 0.0227* 
 G-3(a) 0.0272* 
 G-1(a) 0.2235 
 G-3(b) 0.9661 
 G-2(b) 0.9991 
 
*statistically significant at p value ≤ 0.05 
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Table (3.5): Comparison of each pair using Students' Sample t test: 
Connected letters report 
Levels not connected by same letter are significantly different. 
 
Group     Mean 
G-1(b) A      14.51 
G-2(a) A      13.23 
G-3(a) A B    11.52 
G-1(a) A B C  9.81 
G-3(b)   B C D 5.55 
G-4     C D 3.41 
G-2(b)      D 2.35 
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Table (3.6): Ordered differences report between the various immunized 
groups  
Comparison Difference P value Difference 
G-1(b) G-2(b) 12.16 0.0006*  
G-1(b) G-4 11.09 0.0016*  
G-2(a) G-2(b) 10.88 0.0019*  
G-2(a) G-4 9.81 0.0046*  
G-3(a) G-2(b) 9.17 0.0077*  
G-1(b) G-3(b) 8.96 0.0090*  
G-3(a) G-4 8.11 0.0172*  
G-2(a) G-3(b) 7.68 0.0235*  
G-1(a) G-2(b) 7.47 0.0273*  
G-1(a) G-4 6.40 0.0563  
G-3(a) G-3(b) 5.97333 0.0739  
G-1(b) G-1(a) 4.69333 0.1566  
G-1(a) G-3(b) 4.26667 0.1967  
G-2(a) G-1(a) 3.41333 0.2996  
G-3(b) G-2(b) 3.2 0.3304  
G-1(b) G-3(a) 2.98667 0.3632  
G-3(b) G-4 2.13333 0.5148  
G-2(a) G-3(a) 1.70667 0.6019  
G-3(a) G-1(a) 1.70667 0.6019  
G-1(b) G-2(a) 1.28 0.6954  
G-4 G-2(b) 1.06667 0.7441  
 
*statistically significant at p value ≤ 0.05 
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Fig (3.14): Indirect haemagglutination test in microtiter plate. 
 
 
 
 
–The end points of Ab titre is the highest dilution of tracheobronchial lavage 
that gave visible positive agglutination of RBCs. 
–In haemagglutination negative wells RBCs form a button at the bottom of 
the well. 
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Fig (3.15): Agar gel precipitation test. 
 
 
 
 
 
–Prepheral wells were filled with tracheobronchial lavage of individual rat. 
–Central well contained P. multocida whole cell lysate. 
–Precence of mucosal specific P. multocida antibodies is indicated by the 
formation of strong precipitation lines (band). 
–Continuity of the line indicates mucosal Ab recognize a common Ag of P. 
multocida whole cell lysate. 
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CHAPTER FOUR 
DISCUSSION 
 
The mucosal surface of the respiratory tract represents one of the 
principle portals of entery for most animal pathogen. Most of mucosal 
surfaces are replete with organized follicles and scattered antigen reactive or 
sensitized lymphocytes (Macpherson, McCoy, Johansen and Boandzaeg, 
2007). Therefore, immune response to mucosal pathogens generates 
effectors humoral and cell-mediated immune responses, which may lead to 
protection at mucosal surface. However, the control of haemorrhagic 
septicaemia remains a problem because the current vaccines are not 
sufficiently efficacious and require repeated administration and most of them 
are administered parenterally and may not effectively induce mucosal 
immune response in the respiratory tract (Smith, Babiuk and Stockdale, 
1981; Jaffari, Gill, Bhatti and Raza, 2006 and Cox et al., 2006). For 
instance, the bactrins made from P.multocida have been available for many 
decades but with little effect in preventing the disease. Nonetheless, 
investigation into the immunogenic potential of P.multocida over the last 
several years have led to the development of a variety of 
immunoprophylactic agents but none of these has yet replaced the old 
bactrin vaccines.  
In this study, the primary reason for using intranasal route of 
immunization is that P.multocida infection affects or initiates the infectious 
process at the mucosal surface of the upper respiratory tract and mucosal 
application of P.multocida broth bactrin is required to induce a local 
antibody response. For most of respiratory tract infections, the induction of 
local immunity is crucial for optimal protection (Cox et al., 2006). The 
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induction of SIgA represents the main effectors mechanism of the local 
adaptive immune response and thus represents the primary goal for mucosal 
vaccine (Gerdts et al., 2006). This implicates that vaccination strategies 
should induce effectors mechanisms which help to prevent P.multocida 
establishment and their subsequent invasion in the first place. It is believed 
that one way of achieving this goal is vaccination through mucosal surface 
itself in order to generate an effective local antibody response. This is 
inconsistent with the findings of Zamri-saad, Effendy, Israf and Azmi.  
(1999) who reported that intranasal immunization not only induces a local 
immune response, but also prime systemic responses and mimics the 
oronasal route of infection in natural disease.  
The present study was designed to evaluate the immunogenicity of   
P.multocida in rats using intranasal route of immunization and the effect of 
mucosal adjuvants as well as vaccine-adjuvant ratio. High antibody activity 
was detected in TB lavage obtained from intranasally immunized rats and 
found to be specific to P.multocida by indirect haemagglutination assay 
(IHA) and gel diffusion precipitation test (GDPT) (fig 3.14 and 3.15). 
In GDPT sharp precipitation lines were obtained using TB lavage 
from  P.multocida immunized rats of G1b, G2a and G3a, that received the 
broth bactrin-adjuvant mixture as depicted in fig (3.15). These finding are in 
agreement with the findings of Suckow, Boweosock, Nielsen, and Grigdesby 
(1996) who demonstrated antibody activity in TB lavage of rabbit 
immunized with co-administration of potassium thiocyanate extract of 
P.multocida and cholera toxin as an adjuvant, than with the extract alone. 
These authors also reported protective effect of these locally produced Ab to 
challenge. Moreover, IHA assay revealed high Ab titres in TB lavages of 
rats that received P. multocida broth bactrin adjuvant mixture fig (3.3), (3.6) 
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and (3.9). These findings substantiate the results of Jarvinin, Hogenesch, 
Suckow, and Bowersock, (1998) who induced a protective local antibody 
response in rabbits. Furthermore, Smith et al., (1981) assumed that the route 
of natural infection by P. multocida is via the respiratory tract and he 
suggested that local defence mechanisms were important in preventing the 
establishment of infection. In this study, rats of G1b that received P. 
multocida broth bactrin in olive oil in ratio 2:1 gave high Ab activity in their 
TB lavage as determined by IHA assay in comparison to G4 that received 
the plain broth bactrin vaccine (P=0.0082) as shown in table (3.1), (3.3), 
(3.4), (3.5) and (3.6) and fig (3.2), (3.3) and (3.12).  
Similar high Ab activity was demonstrated in TB lavage of rats of G2a and 
G3a that received P. multocida broth bactrin in sesame oil and vitamin D3 in 
the ratio 1:1 respectively, in comparison to rats of G4 (P≤ 0.005) as shown 
in table (3.1), (3.2), (3.3) and (3.4) and fig (3.4), (3.6), (3.7), (3.9) and 
(3.12).This local high Ab activity in TB lavage  agrees with the finding of 
previous studies that showed mucosal but not subcutaneous immunization 
had resulted in high production of Ab response of SIgA isotype (Butler, 
Swanson, Richerson, Ratajczat, Richards and Suelzer, 1982 and Suckow, 
Boweosock, Nielsen and Grigdesby, 1996). Furthermore, intranasal 
immunization caused an increased IgA Abs level in nasally associated 
lymphoid tissue, in the upper respiratory tract, as well as the bronchial-
associated lymphoid tissue (Lu, Pakes, Massey and Slefann, 1987). The 
presence of IgA Abs has been shown to be important in blocking bacterial 
adhesion and antigen uptake across the mucosal membrane (Suckow et al., 
1996 and Macpherson et al., 2007). Thus, if P.multocida could be eliminated 
at the site of infection by locally produced antibodies, then further systemic 
damage and possible death can be prevented. Therefore, induction of a 
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distinct IgA isotype that dominates mucosal antibodies constituted a strong 
evidence for local immune system structurally and functionally distinct from 
systemic compartment (Macpherson et al., 2007). Studies that compared 
humoral immunity at mucosal surface with serum immune response had 
repeatedly shown a separation between secretory and systemic immune 
responses (Suckow et al., 1996; and Cox et al., 2006). Mucosal surfaces 
represent a critical component of mammalian immunologic repertoire. The 
major Ab isotype in external secretion is SIgA and approximately 40 mg of 
IgA is produced by kg body weight and IgA synthesis is about twice the a 
mount of IgG produced daily in man (Conley and Delacroix, 1987). This 
could explain the high IHA titre obtained in TB lavage of intranasally 
immunized rats as depicted in table (3.1), (3.2), (3.3) and (3.4) and fig (3.1), 
(3.2), (3.4), (3.5), (3.7) and (3.8). 
Intranasal immunization has been shown to induce expression of L- 
selectin as well as α-4β7 integrin on sensitized lymphocytes to favour their 
mucosal homing (Cox et al., 2006; Gerdts et al., 2006, and Macpherson et 
al., 2007). In this study, the booster dose of P. multocida broth bactrin was 
found necessary for prolonged and strong response as the vaccine is dead 
vaccine and the immune response that follows a single inoculation of a dead 
antigen usually falls to a negligible level within few weeks, but it can be 
rapidly revived by secondary or booster dose as has been suggested in this 
study. Furthermore, since the effectiveness of P. multocida broth bactrin 
vaccine is expected to be much lower than live vaccine, we incorporated 
mucosal adjuvant as a means of a delivery system that was needed to 
enhance the uptake of the vaccine antigen and increase the induction of local 
immune response fig (3.3), (3.6), (3.9), (3.10), (3.11) and (3.12).  From this 
study, it seems that intranasal immunization induces high Ab titre in the 
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respiratory tract of rats as it was reported by Jarvinen, Hogenesch, Suckow 
and Bowersock, 1998) and is an effective route to control P. multocida 
infection. Moreover, Smith, et al., (1981) reported that intranasal 
immunization conferred better protection for intranasal challenge than did 
intramuscular immunization and showed an accelerated pulmonary clearance 
of P. multocida after intranasal immunization. However, the method of 
vaccine delivery might be viewed as impractical when vaccinating large 
number of animals, but the efficacy of mucosal vaccination suggests that it 
may be possible to eventually deliver such vaccines by an alternative route 
such as oral route to induce a mucosal immunity at the respiratory tract. This 
is inconsistent with the notion that the mucosal immune system is highly 
compartmentalized but is in perminant contact with each other providing a 
wide variety of possible route of immunizations (Macpherson et al., 2007). 
For instance, earlier studies by Ringler, Peter and Keren, (1985) 
demonstrated the development of antibody activity to P. multocida capsular 
antigens in nasal lavage and sera following intranasal and conjunctival 
immunization. Furthermore, mucosal delivery of a vaccine could provide a 
safe, practical and effective means of protection in animals without concern 
for the development of infection site reaction, or discomfort from parenteral 
immunization (Cox et al., 2006).  
Although immunity to haemorrhagic septicaemia was demonstrated in 
appropriately immunized animals, there are still many unanswered questions 
regarding the mechanisms involved. Most of these studies tell little about the 
means by which the vaccinated hosts control growth of P. multocida in vivo 
at early stages of infection at the respiratory tract (Cox et al., 2006). 
Divergent results regarding route and form of the vaccine antigen require 
further investigation in the light of our present findings and extrapolation 
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from present result and these of (Smith et al., 1981; Suckow et al., 1996 and 
Jarvinen et al., 1998) tend to support our hypothesis that protection from 
respiratory infection is best achieved through intranasal or other mucosal 
route. Therefore, in developing vaccine against haemorrhagic septicaemia it 
seems that mucosal route and mucosal adjuvant are the key players for 
inducing a protective local immune response. Nonetheless, mucosal 
vaccination is proving to be one of the greatest challenges in modern vaccine 
development. Although mucosal vaccination is highly beneficial for 
achieving protective immunity, yet it remains a difficult task (Cox et al., 
2006 and Gerdit et al., 2006). Adjuvants have been used for the last 8 
decades to enhance the immune response of animals to vaccine antigen. 
Hence, the development of mucosal vaccine depends on efficient antigen 
delivery systems to present the vaccine antigen to the mucosal system. 
Therefore, the goal of vaccination is to stimulate a strong protective and long 
lasting immune response to the administered antigen. For achievement of 
these objectives, a potent adjuvant and novel vaccine antigen and vaccine 
strategy are required to make the vaccine sufficiently immunologic to 
initiate a potent immune response at the respiratory tract. Therefore, 
vaccination requires optimal mucosal adjuvants, including 
immunopotentiator and delivery system that offer long term protection from 
infectious diseases of the mucosal surfaces in man and animals.             
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CONCLUSION 
 
1. Mucosal adjuvant plays a pivotal role in inducing a local immune 
response at mucosal surfaces when mixed with mucosal vaccines. 
2. High Ab titre specific to P. multocida were present in TB lavage of 
intranasally immunized rats as was determined by IHA assay and 
GDPT. 
3. Our results suggest that intranasal immunization and use of mucosal 
adjuvants are important delivery system for P. multocida derived 
immunogen to induce a local immune response and this is probably 
achieved through antigen targeting to the APC. The Ab titres in G1, 
G2 and G3 are statistically significant compared to rats in G4 that 
received plain P. multocida vaccine without an adjuvant. 
4.  P. multocida broth bactrin adjuvant ratio 1:1 was found optimal for 
sesame oil and vitamin D3 to induce high Ab titres in TB lavage of 
intranasally immunized rats, whereas vaccine- adjuvant ratio of 2:1 
was found optimal for olive oil to induce high Ab titre compared to 
rats in G4.   
 
 
 
 
 
 
 
 
 
 72
RECOMMENDATIONS 
 
1. Mucosal immunization should be adopted for protection of mucosal 
surfaces against colonization and invasiveness by pathogenic 
microorganisms. 
2. Further investigations are required to study the efficacy of intranasal 
immunization to challenge with P. multocida. 
3. Divergent results regarding routes of administration and form of P. 
multocida vaccine require further investigation, but extrapolation from 
our present results and those of others, in many other systems tend to 
support our hypothesis that protection is best achieved by 
immunization via intranasal route or an alternative mucosal route.   
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